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1  Summary 
Apoptotic cell (AC)-derived factors alter the physiology of macrophages (MΦs) 
towards a regulatory phenotype that is characterized by enhanced production of 
anti-inflammatory  mediators,  an  attenuated  pro-inflammatory  cytokine  profile 
and reduced nitric oxide (NO) formation. Impaired NO production in response to 
ACs  or  AC-conditioned  medium  (CM)  is  facilitated  by  arginase II  (ARG II) 
expression, which competes with inducible NO synthase for L-arginine. 
In  this  study,  I  investigated  the  signaling  pathway  that  allowed  CM  to  up-
regulate  ARG II  in  MΦs.  A  sphingolipid,  further  identified  as  sphingosine-1-
phosphate (S1P), was required but authentic S1P alone only produced small 
effects. S1P acted synergistically with a so far unidentified factor to elicit high 
ARG II  expression.  S1P  signaled  through  S1P  receptor 2  (S1P2),  since  the 
S1P2-antagonist JTE013 and siRNA knock-down of S1P2 prevented ARG II up-
regulation. Further, inhibition and knock-down of extracellular signal-regulated 
kinase 5 (ERK5) attenuated CM-mediated ARG II protein induction. Exploring 
ERK5-dependent  transcriptional  regulation,  promoter  deletion  and  luciferase 
reporter  analysis  of  the  murine  ARG II  promoter  (mpARG II)  suggested  the 
involvement of cyclic  adenosine monophosphate (cAMP) responsive element 
binding  protein  (CREB).  This  was  confirmed  by  EMSA  analysis  and  decoy-
oligonucleotides scavenging CREB, thereby preventing it from activating target 
genes and thus, blocking ARG II expression. I concluded that AC-derived S1P 
binds to S1P2 and acts synergistically with other factors to activate ERK5 and 
concomitantly CREB. This signaling cascade shapes an anti-inflammatory MΦ 
phenotype by ARG II induction. 
Further  investigations  of  ERK5-dependent  CREB  activation  suggested  an 
indirect mechanism implying that ERK5 inhibited phosphodiesterase 4 (PDE4) 
and thus, prevented hydrolysis of cAMP. Since S1P-dependent ERK5 activation 
presumably inhibited PDE4, subsequent cAMP accumulation led to enhanced 
PKA  activity  and  CREB-mediated  transcription.  The  unidentified  factor(s) 
besides S1P probably provoked the required elevation of cAMP production in 
MΦs. Indeed, pharmacological inhibition of cAMP-producing adenylyl cyclase 
with SQ22536 as well as cAMP-dependent protein kinase A (PKA) with KT5720 
suggested  cAMP  to  be  involved  in  CM-mediated  ARG II  up-regulation. Summary    2 
Furthermore,  forskolin-dependent  activation  of  adenyly  cyclase  and 
simultaneous  rolipram-mediated  inhibition  of  PDE4  mimicked  CM-induced 
ARG II expression. 
Considering these findings, I propose that one or several unidentified factors in 
CM provoke cAMP production in MΦs. In parallel, AC-derived S1P activates 
ERK5,  which  inhibits  PDE4-dependent  cAMP  hydrolysis,  further  raising 
intracellular  cAMP  levels.  Thus,  unrestricted  continuous  cAMP  signaling  via 
PKA/CREB, results in a time-dependent and sustained ARG II induction. Zusammenfassung    3 
2  Zusammenfassung 
Apoptotische Zellen (ACs) setzen Faktoren frei, die die biologischen Reaktionen 
von Makrophagen (MΦs) beeinflussen, indem sie einen regulatorischen MΦ-
Phänotyp induzieren. Dieser ist sowohl durch eine erhöhte anti- als auch eine 
verminderte  pro-inflammatorische  Botenstoffproduktion,  sowie  durch  eine 
reduzierte Stickstoffmonoxid(NO)-Synthese gekennzeichnet. Die Reduktion der 
NO-Produktion durch ACs oder AC-konditioniertes Medium (CM), erfolgt durch 
Induktion der Arginase II (ARG II), die mit der NO-Synthase um das Substrat L-
Arginin konkurriert. 
In  der  vorliegenden  Arbeit  untersuchte  ich  die  CM-induzierten,  zellulären 
Signalwege, die zur ARG II Expression in MΦs führen. Das im CM vorhandene 
Sphingolipid  Sphingosin-1-Phosphat  (S1P)  war  erforderlich  für  die  ARG II 
Induktion. Da authentisches S1P alleine nur geringe Effekte zeigte, wirkte es 
höchstwahrscheinlich  synergistisch  mit  einem  oder  mehreren,  bis  jetzt 
unidentifizierten, Faktoren um eine starke ARG II Expression auszulösen. Dabei 
aktivierte S1P den S1P Rezeptor 2 (S1P2), da der S1P2-Antagonist JTE013 und 
die  Inhibition  der  Genexpression  durch  siRNA  die  ARG II  Induktion 
verhinderten.  Weiter  konnte  die  CM-bedingte  ARG II  Proteininduktion  durch 
Hemmung und siRNA Knockdown der ‚extracellular signal-regulated kinase 5’ 
(ERK5)  reduziert  werden.  Die  Untersuchung  der  ERK5-vermittelten 
Transkriptionsregulation durch Luziferase-Reporteranalysen unter Verwendung 
von Deletions-Konstrukten des murinen ARG II Promotors (mpARG II) deutete 
auf die Beteiligung des ‚cyclic adenosine monophosphate (cAMP) responsive 
element  binding  protein’  (CREB)  an  der  ARG II  Regulation  hin.  Dies  wurde 
durch  EMSA-Analysen  und  den  Einsatz  von  Oligonukleotiden,  die  spezifisch 
CREB binden, bestätigt. Hier kann das an Oligonukleotide gebundene CREB 
seine  Zielgene  nicht  aktivieren  und  dementsprechend  auch  nicht  die 
Transkription der ARG II induzieren. Daraus schließe ich, dass S1P in CM zur 
ARG II Induktion in MΦs beiträgt, indem es an S1P2 bindet und synergistisch 
mit anderen Faktoren zur Aktivierung von ERK5 und anschließend von CREB 
führt.  Diese  Signalkaskade  induziert  einen  anti-inflammatorischen  MΦ 
Phänotyp, indem sie ARG II hochreguliert. Zusammenfassung    4 
Die weitere Untersuchung der ERK5-vermittelten CREB Aktivierung ließ einen 
indirekten  Mechanismus  vermuten,  bei  dem  ERK5  die  Phosphodiesterase 4 
(PDE4)  hemmt  und  damit  den  Abbau  von  cAMP  verhindert.  Da  die  S1P-
abhängige  ERK5  Aktivierung  PDE4  vermutlich  inhibiert,  steht  der  PKA  mehr 
cAMP  zur  Verfügung,  um  CREB  zu  aktivieren.  Der/die  unidentifizierte(n) 
Faktor(en) neben S1P bewirkte(n) wahrscheinlich die benötigte cAMP-Synthese 
in  MΦs.  In  der  Tat  verringerte  die  pharmakologische  Hemmung  der  cAMP-
produzierenden  Adenylatzyklase  mit  SQ22536,  sowie  der  cAMP-aktivierten 
Proteinkinase A  (PKA)  mit  KT5720,  die  CM-vermittelte  ARG II  Induktion. 
Außerdem imitierten die Aktivierung der Adenylatzyklase durch Forskolin und 
die gleichzeitige Hemmung der PDE4 durch Rolipram die CM-bedingte ARG II 
Induktion. 
Angesichts  dieser  Befunde  schlage  ich  vor,  dass  ein  oder  mehrere 
unidentifizierte Faktoren im CM zur cAMP-Produktion in MΦs führen. Parallel 
dazu  aktiviert  S1P  aus  ACs  ERK5,  wodurch  PDE4  inhibiert  und  damit  die 
cAMP-Hydrolyse  gehemmt  wird.  Auf  diese  Weise  bewirkt  das  anhaltende 
cAMP-Signal die PKA-vermittelte CREB Aktivierung, die die zeitabhängige und 
nachhaltige ARG II Expression verursacht. 
 Introduction    5 
3  Introduction 
3.1  Homeostasis and apoptotic cell death 
3.1.1 Tissue homeostasis 
The concept of homeostasis was developed by Walter Bradford Cannon and 
popularized  in  its  book  The  Wisdom  of  the  Body  published  in  1932. 
Homeostasis (Greek: hómos = similar, histemi = standing still) is defined as the 
property  of  an  organism  to  regulate  internal  environments  and  maintain  a 
stable,  constant  condition  by  adjusting  its  physiological  processes.  In  adult 
organisms,  the  number  of  cells  is  kept  relatively  constant.  The  control 
mechanism  ensuring  this  tissue  homeostasis  is  achieved  by  fine-tuning  of 
cellular  signaling,  resulting  in  a  balanced  rate  of  mitosis  and  cell  death. 
Dysregulation of these signaling pathways may cause serious disorders, like the 
development of  cancer  in  case  cells  divide  faster  than  they  die,  or  cell  loss 
leading to organ dysfunction if cells divide slower than they undergo apoptotic 
cell death. 
3.1.2 Apoptosis 
The process of cell death was first discovered in 1842 by Carl Vogt and more 
precisely described in 1885 by Walther Flemming, but it was not until 1965 that 
John  Foxton  Ross  Kerr  was  able  to  discriminate  between  programmed  cell 
death called apoptosis (Greek: apo = from, ptosis = falling) and traumatic cell 
death  or  necrosis  (Greek:  nékros  =  dead)  using  electron  microscopy  (Kerr, 
1965). The term apoptosis, used in Greek for the ‘dropping off’ of leaves from 
trees,  was  proposed  by  James  Cormack,  professor  of  Greek  language 
(University of Aberdeen, Scottland), in 1972 to describe the natural process of 
cell  death  in  multicellular  organisms.  The  function  of  apoptosis  consists  in 
removing old, damaged or infected cells to spare the surrounding tissue from 
detrimental cellular constituents that would be released in case of necrosis, thus 
contributing to tissue homeostasis. 
Apoptosis  involves  biochemical  events  leading  to  morphological  changes  of 
cells  including  cell  shrinkage,  loss  of  membrane  asymmetry,  blebbing, 
chromatin  condensation,  DNA  and  nuclear  fragmentation.  Cell  disintegration Introduction    6 
occurs  by  formation  of  so-called  ‘apoptotic  bodies’  with  intact  membrane 
integrity (Kerr et al., 1972; Wyllie et al., 1980). The whole process of apoptosis 
is  tightly  regulated,  energy-dependent  and  immunologically  ‘silent’  when 
terminated  properly  through  clearance  of  apoptotic  bodies  by  professional 
phagocytes. In contrast, necrosis caused by traumata, such as toxins, ischemia, 
mechanical stress or heat, provokes cell swelling and membrane rupture. As a 
consequence,  cellular  constituents  are  released  into  the  surrounding  tissue 
subsequently causing inflammation (Savill et al., 2002; Savill and Fadok, 2000) 
(FIGURE 3.1). 
 
FIGURE 3.1: Scheme of apoptosis vs. necrosis. 
During  apoptosis,  cells  are  degraded  to  ‘apoptotic  bodies’  and  removed  without 
provoking  inflammation.  Necrotic  cells  on  the  other  hand  loose  their  membrane 
integrety, thereby releasing cellular constituents and causing inflammation. Introduction    7 
When the phagocytic capacity is over-saturated in vivo, apoptotic cells (ACs) 
undergo ‘secondary necrosis’, which provokes inflammation and might induce 
autoimmunity (Albert, 2004; Savill et al., 2002). 
3.2  Phagocytosis of apoptotic cells 
In  order  to  prevent  secondary  necrosis  and  the  implicated  inflammatory 
consequences,  ACs  have  to  be  removed  quickly.  This  termination  of  the 
apoptotic program is achieved by professional phagocytes, e.g. macrophages 
(MΦs) and can be subdivided into three steps. First, phagocytes are attracted to 
the  site  of  apoptosis,  then  they  specifically  recognize  ACs,  and  finally  they 
engulf ACs and their ‘apoptotic bodies’. 
3.2.1 Phagocyte attraction 
As  phagocytes  may  not  be  in  close  proximity  to  ACs,  they  have  to  obtain 
molecular  signals  directing  them  correctly.  The  mediators  of  such  molecular 
signals  are  called  chemoattractants  and  some  have  been  identified  and 
reported  to  be  secreted  by  ACs.  For  example,  apoptotic  fibroblast-derived 
thrombospondin 1 (TSP1) was shown to recruit MΦs and, as a heterodimer with 
CD36 on the fibroblast, further to signal for recognition of ACs (Moodley et al., 
2003). Furthermore, calcium-independent phospholipase A2 (iPLA2) is activated 
during  apoptosis  and  hydrolyzes  the  membrane  glycerophospholipid 
phosphatidylcholine  thereby  releasing  lysophosphatidylcholine  (LPC),  which 
induces monocyte and MΦ migration in vitro and in vivo (Lauber et al., 2003) 
probably by binding to the G protein coupled receptor G2A (Peter et al., 2008). 
In addition to glycerophospholipid metabolism, sphingolipid metabolism is also 
active  during  apoptosis,  producing  among  others  sphingosine-1-phosphate 
(S1P)  (Weigert  et  al.,  2006),  which  has  chemoattractant  properties  towards 
monocytes  and  MΦs  in  vitro  (Gude  et  al.,  2008).  ACs  probably  also  recruit 
leukocytes by mimicking the action of IL-8, which is known as a potent cytokine 
mediating  leukocyte  infiltration  into  inflamed  tissues  (Baggiolini  et  al.,  1989). 
Furthermore, IL-8 has also been reported to contribute to monocyte recruitment 
in  vitro  by  triggering  firm  binding  of  monocytes  to  an  endothelial  monolayer 
expressing E-selectin (Gerszten et al., 1999). Indeed, during apoptosis, cells 
release the endothelial monocyte-activating polypeptide II (EMAP II) by cleaving Introduction    8 
aminoacyl-tRNA synthetase, an enzyme crucially involved in protein translation. 
EMAP II is able to mimic IL-8 by binding to the IL-8 receptor on MΦs (Wakasugi 
and  Schimmel,  1999).  However,  ACs  also  secrete  chemorepellants  like 
lactoferrin,  a  potent  inhibitor  of  granulocyte  migration  in  vitro  and  in  vivo 
(Bournazou et al., 2009). Thus, ACs tightly regulate inflammatory processes by 
recruiting phagocytes and ensuring their clearance on the one hand, and by 
preventing the attraction of additional inflammatory cells on the other. 
3.2.2 Recognition and removal of apoptotic cells 
The recognition and phagocytosis of ACs in vivo is achieved by a multiplicity of 
membrane  receptors.  Since  the  identification  of  the  first  MΦ  receptor 
(vitronectin receptor (VnR)(αvβ3-integrin)) mediating up-take of ACs (Savill et al., 
1990), further in vitro studies indicate that phagocytosis of ACs is an extremely 
complex process. Many phagocyte receptors, different bridging molecules as 
well  as  several  surface  markers  of  ACs  called  apoptotic  cell-associated 
molecular patterns (ACAMPs) are involved in this procedure. The complexity of 
this process probably facilitates specific recognition, improved binding and an 
increased phagocytic potential. The involvement of the different receptors in the 
termination of apoptosis is discussed in the following sections. 
3.2.2.1  Innate recognition of ‘nonself’ molecules by phagocytes 
Some phagocyte receptors that mediate AC up-take are elements of the innate 
immune system, like the lipopolysaccharid (LPS) receptor CD14 (Devitt et al., 
1998), the complement fragment 1 (C1q) (Taylor et al., 2000) and proteins of 
the collectin family (Ogden et al., 2001; Schagat et al., 2001) (see FIGURE 
3.2 A). During innate immunity, they initiate inflammatory and immune reactions 
in response to pathogens (Savill et al., 2002). ‘Eat me’ signals on the surface of 
ACs  were  denominated  ACAMPs  in  accordance  with  the  designation  for 
recognition  molecules  on  the  surface  of  pathogens,  so-called  pathogen-
associated  molecular  patterns  (PAMPs).  Despite  these  similarities,  unlike 
phagocytosis  of  pathogens,  the  up-take  of  ACs  does  not  provoke  a  pro-
inflammatory response, but induces an active anti-inflammatory one. This points 
to a mechanism, which in spite of being initiated by the same receptors, triggers 
different signaling cascades with opposite effects (Savill et al., 2002). Introduction    9 
3.2.2.2  Recognition of modified ‘self’ molecules by phagocytes 
Beside  the  receptors  mentioned  in  3.2.2.1,  ACs  are  also  recognized  by 
receptors, which are described to be responsible for detection of damaged or 
modified  ‘self’  molecules.  Examples  for  such  receptors  are  the  class-A 
scavenger receptor (SRA), the class-B scavenger receptor CD36, the lectin-like 
oxidized  low-density  lipoprotein  receptor 1  (LOX1)  and  CD68,  known  to 
participate  in  endocytosis  of  oxidized  low  density  lipoprotein  (oxLDL).  These 
receptors also recognize ACs and facilitate their clearance (Boss et al., 1998; 
Platt et al., 2000; Ren et al., 1995; Savill et al., 1992) (see FIGURE 3.2 B). 
Along this line, oxidation of surface molecules on ACs seems necessary for 
recognition/phagocytosis  by  MΦs  (Chang  et  al.,  1999;  Kagan  et  al.,  2003; 
Kagan et al., 2002). In this context, it was shown that monoclonal antibodies 
against oxLDL bind to ACs thereby preventing their phagocytosis (Chang et al., 
1999). Beyond that, Kagan et al. showed that binding and activation of the Fas-
receptor provoked reactive oxygen species (ROS) production in Jurkat cells and 
subsequent  oxidized  cytochrome c-dependent  oxidation  and  presentation  of 
phosphatidylserine  (PtdSer)  on  the  outer  leaflet  of  the  plasma  membrane  of 
ACs.  The  authors  observed  that  phagocytosis  of  apoptotic  Jurkat  cells  was 
inhibited by superoxide dismutase and catalase, which prevented oxidation of 
PtdSer  while  allowing  it  to  remain  externalized  on  these  cells,  suggesting 
oxydized  PtdSer  to  be  a  prerequisite  for  recognition.  Apart  from  some 
exceptions (Stowell et al., 2009), PtdSer is usually located in the inner leaflet of 
plasma  membrane  and  this  assymmetry  is  ensured  by  aminophospholipid 
translocase. During apoptosis, PtdSer is transported by a flip-flop mechanism to 
the  outer  leaflet  of  the  plasma  membrane,  a  process  whose  underlying 
mechanisms were not uncovered yet, but which seems to be based on inhibition 
of the translocase (Verhoven et al., 1995) and on Ca
2+ and phosphorylation-
dependent  activation  of  a  lipid  scramblase  (Frasch  et  al.,  2000).  However, 
PtdSer  externalization  during  necrotic  cell  death  has  also  been  reported  in 
some cells (Brouckaert et al., 2004), which then are engulfed by MΦs. Similar to 
ACs,  such  a  clearance  of  NCs  does  not  induce  inflammation,  thereby 
suggesting PtdSer as a general marker of different types of cell death sharing 
anti-inflammatory properties. Originally, Fadok et al. assumed to have identified 
a specific PtdSer receptor (PtdSerR) (Fadok et al., 2000). However, the role of Introduction    10 
this presumed PtdSerR in phagocytosis has been refuted by some works (Bose 
et al., 2004; Cikala et al., 2004), one example being an investigation showing 
that PdtSerR-deficient cells were perfectly capable of recognizing, engulfing and 
responding to ACs (Mitchell et al., 2006). The authors concluded that PtdSerR 
is neither involved in specific innate recognition nor in engulfment of ACs. 
Recent investigations identified Stabilin-2 (Park et al., 2008), Tim4 (Miyanishi et 
al., 2007) and BAI1 (Park et al., 2007) as novel direct PtdSer receptors (Bratton 
and Henson, 2008). Furthermore, PtdSer on ACs can be recognized and bound 
by bridge molecules like Gas6 and protein S (which bind to the tyrosine kinase 
receptor  Mer)  or  milk  fat  globule  epidermal  growth  factor 8  (MGF-E8) 
(recognized by VnR) (Lemke and Rothlin, 2008; Wu et al., 2006), as well as β2-
glycoprotein I  (β2-GPI),  which  attaches  to  the  β2-GPI  receptor  (Cocca  et  al., 
2001) (see FIGURE 3.2 B). In addition, PtdSer on ACs seems to be able to 
activate components of the complement system (iC3b) thereby enhancing the 
up-take  of  ACs  by  MΦs  (Mevorach  et  al.,  1998).  Beside  the  complement 
receptors, integrin and Fc receptors have also been suggested to take part in 
phagocytosis of ACs (Stuart and Ezekowitz, 2005). These observations point to 
a  close  relationship  between  innate  recognition  of  foreign  and  modified  self 
molecules. 
Recently, Caberoy et al. identified tubby and tubby-like protein 1 (Tulp1) as new 
‘eat me’ signals, which enhanced pagocytosis of retinal pigment cells by MΦs. 
Unlike Gas6, protein S or MGF-E8, these bridging molecules (recognized by 
Mer)  lack  PtdSer-binding  activity,  leading  the  authors  to  postulate  other 
unidentified PtdSer-like molecules (Caberoy et al., 2009). Introduction    11 
 
FIGURE 3.2: Mechanisms of apoptotic cell-recognition by macrophages.  
A) The innate recognition of apoptotic cells (ACs) occurs via CD14, β2-integrins binding 
the  opsonic  complement  fragment  inactivated  C3b  (iC3b)  and  CD91/calreticulin  the 
C1q and the mannose-binding lectin (MBL). These receptors respectively their bridging 
molecules  recognize  and  bind  AC-associated  molecular  patterns  (ACAMPs).  B) 
Recognition of ACs as modified ‘self’ is mediated by several scavenger receptors, like 
class-A  scavenger  receptor  (SRA),  CD68,  oxidized  low-density  lipoprotein  (oxLDL) 
receptor 1 (LOX1) and CD36, which bind to oxidized membrane molecules since they 
have  similar  epitopes  to  oxLDL.  Furthermore,  presentation  of  PtdSer  on  the  outer 
leaflet of the plasma membrane of ACs contributes to their recognition by macrophages 
(MΦs). PtdSer is bound either directly by PtdSer receptors, such as Stabilin-2, Tim4 
and BAI1 or indirectly by bridging molecules and their respective receptors. The bridge 
molecule  β2-glycoprotein I  (β2-GPI)  is  recognized  by  the  β2-GPI  receptor,  milk  fat 
globule  epidermal  growth  factor 8  (MGF-E8)  by  the  vitronectin  receptor  (VnR)  and 
Gas6 and protein S by the tyrosine kinase receptor Mer. Other bridging molecules, like 
tubby and tubby-like protein 1 (Tulp1) bind to ACAMPs other than PtdSer and are also 
recognized by Mer. Redistribution of proteins in the plasma membrane of ACs as well 
as phagocytes by ATP-binding cassette transporter 1 (ABC1) may also facilitate this 
sort of recognition. C) Modified CD31 (mod.CD31) on ACs accounts for recognition of 
‘self’ molecules that are unable to dislodge and disperse from phagocytes by strongly 
binding to the phagocytic CD31 and possibly facilitating binding of thrombospondin 1 
(TSP1)  to  MΦ  integrins.  A  further  member  of  the  immunoglobulin  superfamily,  the 
intercellular adhesion molecule 3 (ICAM3) might undergo similar modifications and thus 
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3.2.2.3  Recognition of non-detaching ‘self’ molecules by phagocytes 
The  specific  recognition  of  ACs  also  occurs  by  means  of  molecules,  which 
normally  promote  adhesion  and  movement  of  living  cells,  like  e.g.  the 
intercellular adhesion molecule 3 (ICAM3) or TSP1 (Hughes et al., 1997; Savill 
et  al.,  1992).  Thus,  phagocytes  need  to  discriminate  between  living,  moving 
cells and ACs that have to be engulfed. However, the underlying mechanism 
remains elusive. A study of Brown et al. provides a possible explanation. The 
authors observed that apoptotic leukocytes, in contrast to living ones, cannot 
discern and process detachment signals from MΦs. The homophile connection 
of CD31 between phagocytes and living leukocytes provided repellent signals, 
thereby  ensuring  their  active  detachment. On  the  contrary  the  connection  to 
dying leukocytes transformed the repulsive signals into attracting ones, thereby 
strengthening  the  bond  between  AC  and  phagocyte  and  promoting 
phagocytosis (Brown et al., 2002). Similar to these findings, the immunoglobulin 
ICAM3 might also undergo comparable modifications leading to the same effect 
(Savill  et  al.,  2002)  (see  FIGURE  3.2 C).  Thus,  one  could  assume  that  the 
inability  of  ACs  to  dislodge  and  disperse  from  phagocytes  is  a  general 
mechanism for the up-take of dying cells. Nonetheless, this connection may be 
unsufficient  to  induce  phagocytosis,  so  that  further  signals,  like  e.g.  the 
presentation of PtdSer on the outer leaflet of the plasma membrane, may be 
necessary (Hanayama et al., 2002). 
3.2.2.4  Removal of apoptotic cells 
Following recognition of ACs, phagocytes undergo cytoskeleton rearrangement 
in  order  to  engulf  them.  The  underlying  mechanisms,  linking  AC-recognizing 
receptors of phagocytes and their actin filaments, are still unclear. A candidate 
is  the  CrkII-ELMO-DOCK180  complex  in  the  plasma  membrane,  which 
mediates  cytoskeleton  changes  by  Rac1  activation  and  can  be  activated 
downstream  of  VnR  or  Mer  (Akakura  et  al.,  2004; Wu  et  al.,  2006)  thereby 
possibly linking PtdSer on ACs to phagocytosis. Another mechanism of Rac1 
activation might occur via GULP, a downstream effector of CD91 that interacts 
with ATP-binding cassette transporter 1 (ABC1) on ACs (Lauber et al., 2004). 
Furthermore,  the  crucial  role  of  transglutaminase  type II  (TG II)  for  the 
internalization, but not recognition and binding, of ACs was demonstrated by Introduction    13 
TG II-ablation in mice, which resulted in defective clearance of ACs associated 
with the development of inflammation and auto-immunity (Falasca et al., 2005). 
It is also worth mentioning that the processes of phagocytosis of ACs, necrotic 
cells (NCs) and pathogens are morphologically different. Electron microscopic 
investigations showed that ACs are phagocyted by a zipper-like mechanism, 
while pathogens are usually receptor-mediated endocytozed and NCs (as well 
as  secondarily  NCs)  are  macropinocytozed  (Aderem  and  Underhill,  1999; 
Krysko  et  al.,  2003).  These  differences  reflect  the  complexity  and  strict 
regulation  of  the  different  phagocytic  mechanisms  and  their  effects  on  the 
behavior  of  phagocytes.  Furthermore,  the  process  of  phagocytosis  of  ACs 
seems  to  be  a  unique,  evolutionary  conserved  mechanism,  since  the  anti-
inflammatory  effects  of  ACs  are  independent  of  species  and  the  apoptotic 
stimulus (Voll et al., 1997). 
3.3  Macrophage populations 
MΦs  are  versatile  immune  cells  which,  depending  on  environmental  stimuli, 
acquire diverse functional states. The extremes of this continuum are defined as 
the  classically  activated  M1  and  the  alternatively  activated  M2   phenotype 
(Gordon,  2003).  However,  the  alternative  M2  definition  does  not  satisfy  and 
mirror  the  compelling  evidence  gathered  over  the  last  few  years  any  more, 
since  the  M2  designation  comprises  MΦs  with  dramatic  differences  in  their 
biochemistry  and  physiology  (Edwards  et  al.,  2006).  Mosser  and  Edwards 
proposed a classification of MΦs according to their fundamental functions in 
host  defense,  wound  healing  and  immune  regulation  (Mosser  and  Edwards, 
2008) (see FIGURE 3.3). The authors assumed that there are many different 
‘shades’ of MΦ activation and compared their classification to the three primary 
colours fusing into each other in a colour wheel. Thus, this should illustrate the 
ability  of  MΦs  to  exhibit  characteristics,  shared  by  more  than  one  MΦ 
population. 
3.3.1 M1  phenotype:  classically  activated  or  host  defense 
macrophages 
The M1 MΦ phenotype is established in response to stimuli, rapidly generated 
following  infection  or  injury,  like  the  bacterial  cell  wall  component  LPS  and Introduction    14 
interferon γ  (IFNγ).  M1  MΦs  are  characterized  by  enhanced  microbicidal 
capacity,  ensured  by  the  production  of  pro-inflammatory  mediators  such  as 
tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), IL-6, IL-12, nitric oxide 
(NO) or ROS (Mackaness, 1964; O'Shea and Murray, 2008). 
IFNγ can be produced by innate as well as adaptive immune cells; natural killer 
cells providing an early, generally transient innate source and T helper 1 (TH1) 
cells a sustained adaptive one (Dale et al., 2008). Classical activation of MΦs 
requires  Toll-like  receptor  (TLR)  activation  (e.g.  by  LPS)  and  subsequent 
MyD88-dependent TNF-α expression, which then cooperates with IFNγ in an 
autocrine way. In some cases exogenous IFNγ is dispensable, since some TLR 
ligands TRIF-dependently induce IFNβ production (Yamamoto et al., 2003). The 
importance  of  TLR  activation  and  subsequent  TNF-α  production  for  the 
development  of  M1  MΦs  was  confirmed  by  experiments  using  eukaryotic 
parasites (Leishmania spp.) that failed to trigger TNF-α production in MΦs due 
to their lack of TLR ligands. Indeed, infected MΦs stimulated with exogenous 
TNF-α or with the TLR ligand LPS were able to clear the parasites completely 
(Bogdan and Rollinghoff, 1998). 
Production  of  pro-inflammatory  mediators  is  the  main  feature  of  classically 
activated  MΦs,  thus  ensuring  competent  host  defense.  However,  classical 
activation needs to be tightly controlled, since these factors may be detrimental 
by causing extensive host-tissue damage. In sepsis e.g., overproduction of pro-
inflammatory  cytokines  induces  a  hyperinflammatory  immune  response  often 
provoking severe tissue damage, organ failure, and death (Hotchkiss and Karl, 
2003). Furthermore, IL-1 and IL-6, have been associated with the development 
and  expansion  of  TH17  cells  (Bettelli  et  al.,  2006),  known  for  their  strong 
efficient  recruitment  of  polymorphonuclear  leukocytes  (PMN)  and  thereby 
contributing  to  pathological  inflammatory  autoimmune  diseases,  including 
rheumatoid  arthritis  (Szekanecz  and  Koch,  2007)  and  inflammatory  bowel 
disease (Zhang and Mosser, 2008). 
3.3.2 M2 phenotype: alternatively activated macrophages 
Alternative  activation  of  MΦs,  e.g.  with  glucocorticoids,  IL-4,  IL-13  or  IL-10, 
induces  an  anti-inflammatory  M2  phenotype,  which  is  characterized  by 
attenuated  production  of  pro-inflammatory,  but  enhanced  secretion  of  anti-Introduction    15 
inflammatory mediators such as IL-10, transforming growth factor β1 (TGF-β1) 
and prostaglandin E2 (PGE2). M2 designation regroups several populations of 
MΦs with different biochemistry and function, like wound-healing (M2a), hybrid 
(M2b)  and  regulatory  (M2c)  MΦs  (Mantovani  et  al.,  2004b;  Mosser  and 
Edwards, 2008). 
3.3.2.1  M2a phenotype: wound-healing macrophages 
Alternative activation of MΦs (M2) was originally described to depend on IL-4 
and IL-13 stimulation. Basophils and mast cells are considered to be the main 
early  sources  of  IL-4,  which  is  thought  to be  the first  innate  signal  released 
during  tissue  injury  (Brandt  et  al.,  2000;  Loke  et  al.,  2007).  IL-4  induces 
arginase activity in MΦs, which converts L-arginine to L-ornithine, a precursor of 
polyamines  and  collagen,  thereby  promoting  the  production  of  extracellular 
matrix. Considering their ability to secrete extracellular matrix components and 
their  implied  function  in  wound  healing,  the  classification  of  these  cells  was 
more  recently  specified  as  M2a  or  wound-healing  MΦs  (Mantovani  et  al., 
2004b; Mosser and Edwards, 2008). 
Besides  innate  signaling  induced  by  tissue  injury,  adaptive  TH2  immune 
responses  may  also  promote  the  development  and  maintainance  of  wound-
healing MΦs, since IL-4 and IL-13 are the characteristic cytokines of TH2 cells. 
In vitro, treatment of MΦs with IL-4 and/or IL-13 generates a population of M2a 
cells  unable  to  present  antigens  to  T cells,  accompanied  by  attenuated 
production of pro-inflammatory cytokines as well as NO or ROS. Thus, these 
cells are less efficient at killing intracellular pathogens compared to classically 
activated  MΦs  (Edwards  et  al.,  2006).  Alongside  the  contribution  to  the 
production of extracellular matrix, wound-healing MΦs also show enhanced IL-
10, mannose (MR) and scavenger receptor (SR) expression (Mantovani et al., 
2004b; Stein et al., 1992). Furthermore, the polyamines produced by these cells 
influence the cytokine production and suppress clonal expansion of neighboring 
lymphocytes (Cordeiro-da-Silva et al., 2004). 
Similar to dysregulation of M1 MΦs in autoimmunity, uncontrolled activation of 
wound-healing MΦs is detrimental for the host and has been associated with 
tissue fibrosis in chronic schistosomiasis as well as in asthma (Hesse et al., 
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3.3.2.2  M2b phenotype: hybrid macrophages 
M2b or hybrid MΦs result from exposure to immune complexes in combination 
with  TLR  or  IL-1  receptor  ligands.  These  MΦs  have  immunomodulating 
functions, since they induce consistent TH2 responses. Like other alternative 
activated MΦs, they show enhanced IL-10 and impaired IL-12 expression, but 
on the contrary they still produce pro-inflammatory cytokines, like TNF-α, IL-6 
and IL-1 (Mantovani et al., 2004b; Mosser and Edwards, 2008). M2b MΦs have 
been shown to originate from classically activated M1 MΦs, whose Fcγ receptor 
(FcγR) has been triggered by immune complexes. Thus, ligation of FcγR on M1 
MΦs may invert the influence of an innate immune response, thereby deviating 
TH1  into  TH2  responses.  The  authors  postulated  that  this  phenotypic  switch 
might  be  exploited  to  modulate  pathologies  associated  with  TH1  responses. 
Furthermore, they assumed that TH2 responses following FcγR ligation might 
contribute to an improvement of immunoglobulin G (IgG) responses to weakly 
immunogenic antigens, since they observed that mice injected with M2b MΦs 
produced higher levels of IgG compared to M1 MΦs (Anderson and Mosser, 
2002). 
3.3.2.3  M2c phenotype: regulatory macrophages 
Exposure  of  MΦs  to  environmental  stimuli,  such  as  glucocorticoides,  PGs, 
immune  complexes,  IL-10  and  ACs,  generates  M2c  or  regulatory  MΦs 
(Mantovani  et  al.,  2004b;  Mosser  and  Edwards,  2008).  Recently,  further 
inducers,  like  adenosine  (Hasko  et  al.,  2007),  S1P  (Weigert  et  al.,  2007)  or 
adiponectin (Huang et al., 2008), have been suggested to provoke regulatory 
MΦ  differentiation.  This  designation  refers  to  their  pronounced  immune 
regulatory function due to secretion of high levels of the immunosuppressive 
mediators  IL-10  and  TGF-β1,  and  impaired  production  of  IL-12  (Gerber  and 
Mosser,  2001).  Despite  enhanced  MR  expression  and  the  anti-inflammatory 
similarities,  wound-healing  and  regulatory  MΦs  present  clear  functional  and 
biochemical differences. In contrast to wound-healing MΦs (M2a), regulatory 
MΦs are neither impaired in antigen presentation nor do they contribute to the 
production  of  extracellular  matrix  components  (Mosser  and  Edwards,  2008). 
Furthermore,  regulatory  MΦs  play  an  important  part  in  the  late  stages  of 
adaptive  immune  responses,  their  main  role  consisting  in  dampening  and Introduction    17 
limiting  inflammation  in  order  to  restore  post-inflammation,  but  also  post-
traumatic tissue homeostasis (Bystrom et al., 2008; Mosser, 2003; Ruffell et al., 
2009). 
 
FIGURE 3.3: Macrophage populations.  
The M1 macrophage (MΦ) phenotype is generated by classical activation via LPS and 
IFNγ stimulation. M1 MΦs produce cytotoxic nitric oxide (NO) via indicible NO synthase 
(iNOS) and reactive oxygen species (ROS) as well as pro-inflammatory mediators, like 
TNF-α,  interleukin 1  (IL-1),  IL-6  and  IL-12.  Alternative  M2  MΦ  activation  is  more 
heterogenous and raises three different M2  MΦ phenotypes. IL-4 and IL-13 induce 
wound-healing  MΦs  characterized  by  exibition  of  scavenger  (SR)  and  mannose 
receptors  (MR),  release  of  immunosuppressive  IL-10  and  up-regulation  of  arginase 
(ARG) and consequent production of polyamines and the matrix component collagen. 
Hybrid  MΦs  are  generated  by  stimulation  with  immune  complexes  (IC)  and  toll-like 
receptors  ligands  (TLRL)  or  IL-1  receptor  ligands  (IL-1RL),  and  they  produce  anti-
inflammatory  IL-10  as  well  as  pro-inflammatory  TNF-α,  IL-1  and  IL-6.  Induction  of 
regulatory MΦs is mediated by IL-10. This regulatory phenotype is characterized by 
ARG and MR expression and by release of immunoregulatory factors, like transforming 
growth factor β (TGF-β) and IL-10. 
A growing body of evidence shows that regulatory MΦs may be exploited by 
parasites, viruses and bacteria (Benoit et al., 2008; Kim et al., 2008). These 
pathogens  are  able  to  mimic  stimuli  that  induce  this  MΦ  phenotype.  For 
example,  the  Gram  negative  intracellular  bacterium  Coxiella  burnetti  causes 
host-cell apoptosis. Subsequent clearance of ACs by MΦs polarizes them into Introduction    18 
regulatory  cells  with  impaired  bactericidal  capacity  and  therefore  tolerant 
towards  intracellular  bacterial  growth  (Benoit  et  al.,  2008).  Similar  to  this, 
intracellular  parasites  of  Leishmania  spp.,  that  primarily  replicate  in  MΦs, 
escape  host  defense  by  polarizing  the  latter  to  an  M2c  phenotype.  Indeed, 
these  infected  MΦs  produce  TGF-β  and  IL-10  and  show  impaired  major 
histocompatibility  complex II  (MHCII)  expression  (Bogdan  and  Rollinghoff, 
1998). 
Worth mentioning is also the fact that tumor-associated MΦs (TAMs) may share 
some characteristics with regulatory MΦs (Pollard, 2008). The role of MΦs in 
cancer will be discussed in 3.3.3. 
3.3.2.4  Role of extracellular signal-regulated kinase in regulatory macrophage 
phenotype 
As mentioned above (see 3.3.2.3), there are many stimuli inducing an M2c MΦ 
phenotype, but the underlying mechanism still remains uncharacterized. Lucas 
et al. proposed the extracellular signal-regulated kinase (ERK) to be implicated 
in this phenotypic switch (Lucas et al., 2005). Previously, the same group had 
shown that LPS-mediated production of high levels of IL-12 was abrogated by 
co-ligation of the MΦ Fcγ receptor, accompanied by strong enhancement of IL-
10  production  (Gerber  and  Mosser,  2001).  In  a  further  study,  Lucas  et  al. 
showed  that LPS  stimulation of  MΦs  in  the presence of  immune  complexes 
(Fcγ receptor ligands) resulted in augmented ERK activation and subsequent 
phosphorylation-mediated  histone  modifications  in  the  IL-10 promoter  region. 
The high production of the immunosuppressive cytokine IL-10, which is one of 
the  main  features  of  regulatory  MΦs,  was  prevented  by  pharmacolgical 
inhibition of ERK. Based on these observations, the authors suggested ERK 
signaling to mediate the observed phenotypic switch. 
3.3.2.5  Role  of  cyclic  adenosine  monophosphate  in  regulatory  macrophage 
phenotype 
Recently,  several  reports  suggested  the  potent  immunomodulator  cAMP  to 
account for alternative activation of MΦs (Bystrom et al., 2008; Medeiros et al., 
2009).  Bystrom  et  al.  suggested  cyclic  adenosine  monophosphate  (cAMP) 
signaling in MΦs to control their phenotype during resolution of inflammation. 
The authors isolated and characterized MΦs from the resolving phase of acute Introduction    19 
inflammation  and  accordingly  designated  them  as  resolution-phase  MΦs.  In 
comparison  to  M1  MΦs,  resolution-phase  MΦs  have  far  weaker  bactericidal 
properties.  Furthermore,  they  display  an  anti-inflammatory  phenotype  and 
express cyclooxygenase-2 (COX-2) as well as inducible nitric oxide synthase 
(iNOS)  (Bystrom  et  al.,  2008).  Thus,  the  characteristics  of  these  resolution-
phase MΦs are very similar to those of regulatory MΦs, indicating that these 
MΦ populations are identical. Bystrom et al. convincingly showed that cAMP 
signaling  is  a  prerequisite  for  the  development  of  resolution-phase  MΦs. 
Indeed,  inhibition  of  the  cAMP  pathway  transformed  these  cells  into  pro-
inflammatory M1 MΦs. Inversely, elevation of cAMP in M1 cells converted them 
to  resolution-phase  MΦs  (Bystrom  et  al.,  2008).  Another  study  further 
emphasizes the importance of cAMP in regulatory MΦs. Medeiros et al. showed 
that  COX-dependent  PGE2  production  upon  clearance  of  ACs  potently 
prevented disposal of pathogens in vivo by alveolar MΦs, which secreted high 
levels  of  IL-10.  Furthermore,  they  attributed  these  observations  to 
PGE2/E prostanoid  receptor 2  (EP2)  signaling  and  subsequent  adenylyl 
cyclase-mediated cAMP production (Medeiros et al., 2009). These observations 
indicate that cAMP might participate in the polarization of regulatory MΦs. 
3.3.3 M2 macrophages in cancer 
Taking into consideration that MΦs discern modified ‘self’ molecules, like e.g. 
ACAMPs  on  ACs  and  thereupon  clear  them,  it  seems  logical  to  postulate 
recognition and elimination of modified tumor cells as well. Unfortunately, many 
studies show that this assumption is not the case. On the contrary, TAMs seem 
to  aquire  biochemical  properties  promoting  tumor  growth  and  progression 
(Lewis and Pollard, 2006). Their presence in solid tumors, which can attain 50% 
of  tumor  mass  in  breast  cancer e.g.  (Murdoch et  al.,  2004),  has  even  been 
correlated with poor survival prognosis for patients (Bingle et al., 2002). 
However, in early stages of cancer, MΦs display a pro-inflammatory M1-like 
phenotype. On the one hand, these classically activated MΦs were shown to be 
cytotoxic  towards  tumor  cells,  thereby  contributing  to  early  eradication  of 
transformed cells (Romieu-Mourez et al., 2006). On the other hand, M1 MΦs 
were reported to contribute to early neoplasia by producing free radicals, thus 
inducing  DNA  damage  that  causes  mutations  and  predisposes  cells  to Introduction    20 
transformation (Swann et al., 2008). Even though opinions on their role are still 
controversial,  there  is  a  general  agreement  about  their  pro-inflammatory 
phenotype. 
During tumor progression and growth, tumor-derived agents induce pronounced 
changes  in  the  physiology  of  MΦs  thereby  promoting  the  development  of 
regulatory cells (Pollard, 2008) with impaired production of tumoricidal factors 
such as TNF-α and NO. Like regulatory MΦs, these TAMs produce high levels 
of  IL-10  and  little  IL-12.  They  can  also  inhibit  immune  responses  to  neo-
antigens  and  prevent  activation  of  neighboring  MΦs  (Biswas  et  al.,  2006). 
Furthermore,  a  recent  study  suggested  that  regulatory  MΦs  promote  tumor 
growth  by  contributing  to  angiogenesis  (Lin  et  al.,  2006). The  importance  of 
TAMs in vascular development, and consequently for tumor malignancy, was 
further  strengthened  in  a  breast  cancer  mouse  model.  Indeed,  preventing 
infiltration  of  MΦs  into  the  tumor  retarded  its  development  due  to  defective 
vascularization (Lin et al., 2006). Along this line, infiltration of TAMs was also 
correlated with high blood vessel density in tumors (Yu and Rak, 2003). Taken 
together,  these  observations  convincingly  suggest  that  TAMs  promote  tumor 
survival,  growth,  angiogenesis  and  metastasis  formation  as  well  as  immune 
evasion. 
Candidate  inducers  of  M2-like  regulatory  polarization  within  the  tumor 
microenvironment include IL-4, IL-10, TGF-β, PGs, hypoxia and ACs (Knowles 
and Harris, 2001; Liu et al., 2001; Weigert et al., 2007). Lately the assumption 
arose that tumors mis-use the physiological function of MΦs in the resolution of 
inflammation and re-establishment of tissue homeostasis by polarizing them in 
an  AC-similar  way  (Mantovani  et  al.,  2004a;  Weigert  et  al.,  2007).  This 
assumption  was  based  on  studies  showing  that  tumor  regression  could  be 
induced in vivo by preventing MΦ and dendritic cell-mediated AC-recognition 
(Bondanza et al., 2004), and that MΦ cytotoxicity towards viable tumor cells 
could be impaired by addition of apoptotic tumor cells (Reiter et al., 1999). 
3.4  Macrophage polarization by apoptotic cells 
Formerly,  disposal  of  ACs  was  thought  to  be  an  immunologically  neutral 
process, since no release of pro-inflammatory cytokines was observed (Stern et 
al., 1996). The absence of an inflammatory response was attributed to a fast Introduction    21 
phagocytosis of ACs before they could release harmful cellular components in 
the  surrounding  tissue  by  loss  of  membrane  integrity  (Savill  et  al.,  1993). 
However, it was shown that inducers of apoptosis, like e.g. ultraviolet radiation, 
could alleviate inflammatory diseases (Abel, 1995). Thus, the question arose 
whether  ACs  only  fail  to  induce  inflammation,  or  whether  they  also  actively 
suppress the inflammatory response. 
3.4.1 Attenuated pro- and enhanced anti-inflammatory response of 
macrophages towards apoptotic cells 
Studies  in  various  model  systems  showed  that  phagocytosis  of  ACs  is  an 
active, immunosuppressive and anti-inflammatory process. In 1997, Voll et al. 
reported  that  co-incubation  of  apoptotic  lymphocytes  with  LPS-elicited 
monocytes attenuated pro-inflammatory cytokine production of TNF-α and IL-1β 
and increased the release of the anti-inflammatory mediator IL-10 from the latter 
(Voll et al., 1997). Beyond that, a study of Fadok et al. showed that ACs induce 
secretion of TGF-β1, PGE2 and platelet activating factor (PAF) in MΦs probably 
via PtdSer exposure. Furthermore, autocrine signaling of TGF-β1, PGE2 and 
PAF contributed to impaired secretion of pro-inflammatory cytokines, like TNF-
α, IL-1β and IL-8. On the one hand, addition of exogenous TGF-β1, PGE2 or 
PAF  prevented  LPS-mediated  cytokine  production.  On  the  other  hand  LPS-
mediated cytokine production in MΦs, which had phagocyted ACs, could be 
restored  by  scavenging  TGF-β  with  TGF-β  neutralizing  antibodies,  blocking 
COX by indomethacin or by PAF receptor antagonists (Fadok et al., 1998). In 
this context, TGF-β1 was described to impair pro-inflammatory cytokine release 
by activating ERK, provoking up-regulation of mitogen-activated protein kinase 
(MAPK)  phosphatase 1  and  subsequent  inhibition  of  p38-MAPK  and  nuclear 
factor κB (NF-κB) (Xiao et al., 2002). Reduced cytokine expression is generally 
attributed  to  inhibition  of  NF-κB,  since  this  transcription  factor  is  the  major 
transcriptional  regulator  of  cytokine  expression  (Bonizzi  and  Karin,  2004). 
Besides  the  potential  role  of  TGF-β,  the  tyrosine  kinase  receptor  Mer  also 
seems to be an appropriate candidate mediating inhibition of NF-κB. In fact, AC-
dependent inhibition of NF-κB in phagocytes could be prevented by inhibiting or 
knocking down the tyrosine kinase receptor Mer as well as by overexpressing a 
Mer tyrosine kinase-dead mutant (Sen et al., 2007; Tibrewal et al., 2008). This Introduction    22 
points to the implication of PtdSer in this process, since MΦ Mer kinase has 
been reported to bind to PtdSer on ACs via the bridging molecule Gas6 (Wu et 
al.,  2006).  In  addition  to  TGF-β  and  Mer  tyrosine  kinase-dependent  late 
regulation (³ 18 hours), co-activators and co-repressors have been described to 
modulate  NF-κB  activity  at  earlier  times  (Cvetanovic  and  Ucker,  2004). 
Recently,  Jennewein  et  al.  reported  that  AC-mediated  early  inhibition 
(³ 1.5 hours)  of  NF-κB  resulted  from  the  interplay  between  peroxisome 
proliferator-activated receptor γ (PPARγ) and the nuclear receptor co-repressor 
(NCoR). NCoR, a co-repressor binding to NF-κB sites under basal conditions, is 
degraded upon LPS stimulation via the ubiquitination/19S proteasome pathway, 
followed  by  binding  of  co-activators  and  initiation  of  transcription  of  pro-
inflammatory  mediators  (Pascual  et  al.,  2005).  AC-dependent  PPARγ 
sumoylation  in  MΦs  directs  it  to  NCoR,  thereby  inhibiting  proteasomal 
degradation and subsequent release of active NF-κB, thus transrepressing NF-
κB-mediated  promoter  activities  of  pro-inflammatory  cytokines  (Jennewein  et 
al., 2008). Interestingly, another study proposed p50 homodimerization to be 
crucial  for  NF-κB  inhibition  in  tumor-associated  MΦs  (Saccani  et  al.,  2006), 
suggesting that depending on environmental stimuli, distinct signaling pathways 
are initiated, yet with a similar outcome. 
Furthermore,  in  vivo  experiments  on  pneumonias  suggested  AC-dependent 
TGF-β1  secretion from  MΦs  to have  anti-inflammatory  effects  (Huynh  et al., 
2002). Huynh et al. also argued for PtdSer-dependent TGF-β1 release since 
human monomyelocytes, which did not expose PtdSer on the outer leaflet of the 
plasma membrane upon apoptosis, were unable to induce TGF-β1 secretion. 
Along this line, MΦs did not release TGF-β1, when incubated with irradiated 
tumor cells on which PtdSer had been masked with annexin V (Bondanza et al., 
2004). Another more recent study supports the assumption that PtdSer receptor 
activation  signals  towards  TGF-β  production.  The  authors  induced  TGF-β1 
secretion by activating the novel PtdSer receptor Stabilin-2 with anti-Stabilin-2 
antibodies (Park et al., 2008). Although the phagocyte receptor mediating TGF-
β1 secretion is still uncharacterized, transcriptional regulation by MAPKs (p38, 
ERK and Jnk) as well as translational modulation by Rho/PI3K/Akt/mTor seem 
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Worth mentioning is also the fact that phagocytosis per se is not required to 
suppress  inflammation.  Knock-down  studies  on  CD14  as  well  as  CD36/VnR 
deficient mice showed that, despite impaired phagocytosis of ACs, secretion of 
TGF-β was still elevated and TNF-α release was reduced (Devitt et al., 2004; 
Lucas et al., 2006). 
3.4.2 Attenuated nitric oxide and reactive oxygen species formation 
in macrophages in response to apoptotic cells 
MΦs respond to bacteria or bacterial components with an up-regulation of ROS 
and NO production, which mediates in part their bactericidal capacity (Bogdan, 
2001;  Forman  and  Torres,  2002).  Cytotoxic  ROS  formation  in  MΦs,  the  so-
called oxidative burst is triggered by PKCα-mediated phosphorylation of p47
phox, 
activation of Rac1/2 and assembly of the NADPH oxidase complex (Lambeth, 
2004; Larsen et al., 2000). NO production in response to LPS and/or IFN-γ is 
initiated by up-regulation of the iNOS that oxidizes L-arginine to L-citrulline and 
NO (Bogdan, 2001) (see FIGURE 3.4). 
 
FIGURE 3.4: Scheme of the reaction catalyzed by nitric oxide synthase (NOS).  
The substrate of the enzyme NOS (which exists in several isoforms) is the aminoacid 
L-arginine. This aminoacid is hydroxylated twice into nitric oxide (NO) and L-citrulline. 
Several  studies  reported  the  ability  of  ACs  to  impair  ROS  as  well  as  NO 
formation in MΦs (Freire-de-Lima et al., 2000; Johann et al., 2006; Serinkan et 
al., 2005). Serinkan et al. observed that apoptotic Jurkat cells as well as PtdSer-
enriched  viable  Jurkat  cells  inhibited  ROS  production  in  MΦs  in  a  cell-cell-Introduction    24 
contact  dependent  way,  thus  pointing  to  a  PtdSer-triggered  mechanism 
(Serinkan  et  al.,  2005).  Furthermore,  Johann  et  al.  suggested  AC-mediated 
activation of PPARγ to account for inhibition of ROS formation (Johann et al., 
2006). Along this line, activation of PPARγ has been shown to interfere with 
PKCα  translocation  to  the  plasma  membrane  by  a  direct  protein-protein 
interaction,  thereby  abolishing  PKCα-mediated  phosphorylation  of  p47
phox, 
which  is  indispensable  for  NADPH  oxidase  assembly  and  subsequent  ROS 
production (von Knethen et al., 2007). Concerning AC-dependent impairment of 
NO formation, enhanced arginase (ARG) expression seems to play a decisive 
role.  ARG I  and  ARG II  compete  with  iNOS  for  the  common  substrate  by 
metabolizing L-arginine to urea and ornithine (Johann et al., 2007; Morris, 2004; 
Topal et al., 2006) (see FIGURE 3.5). 
 
FIGURE 3.5: Scheme of the reaction catalyzed by arginase (ARG). 
The substrate of the enzyme ARG, which exists in several isoforms, is the aminoacid L-
arginine. This aminoacid is hydrolyzed into L-ornithine and urea. 
Johann  et  al.  proposed  that  impaired  NO  production  resulted  from  TGF-β-
independent up-regulation of ARG II and unaltered iNOS expression (Johann et 
al., 2007), while others suggested a TGF-β/PtdSer-dependent up-regulation of 
ARG I and simultaneous down-regulation of iNOS to account for this inhibition 
(Freire-de-Lima et al., 2006). However, TGF-β-dependent ARG I up-regulation 
occurred late (³ 24 hours) in comparison to inhibition of NO production, pointing 
to  an  early  TGF-β-independent  and  a  late,  at  least  in  part,  TGF-β-mediated 
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3.4.3 Impact  of  soluble  factors  released  from  apoptotic  cells  on 
macrophages 
AC-dependent  polarization  of  MΦs  was  thought  to  require  receptor-ligand 
interactions or phagocytosis-derived signals, but more recent studies show that 
ACs confer immunomodulation by releasing soluble factors. ACs exert direct 
anti-inflammatory  effects  by  secreting  factors  with  immunosuppressive 
properties, like the cytokines IL-4 (Hodge et al., 2002), IL-10 (Gao et al., 1998) 
and  TGF-β  (Chen  et  al.,  2001;  Hodge  et  al.,  2002)  or  the  lipid  mediator 
sphingosine-1-phosphate (S1P) (Weigert et al., 2006). 
3.4.3.1  Effects of IL-4, IL-10 and TGF-β on macrophages 
Besides  IL-4  release  from  ACs,  IL-4  is  primarily  produced  by  basophils  and 
mast cells in response to tissue injury (Brandt et al., 2000). IL-4 rapidly shifts 
the MΦ phenotype towards wound healing. These MΦs fail to present antigens 
to T cells and are impaired in the production of pro-inflammatory cytokines as 
well as ROS and NO (Edwards et al., 2006). 
IL-10  is  a  potent  anti-inflammatory  cytokine,  mainly  secreted  by  regulatory 
T cells, but also by ACs and MΦs themselves. Kuhn et al. reported IL-10 to be 
immunosuppressive,  since  IL-10-deficient  mice  seem  unable  to  constrict 
inflammation and eventually develop chronic intestinal inflammation (Kuhn et 
al.,  1993).  In  accordance,  Gao  et  al.  showed  that  Fas-triggered  apoptotic 
lymphoid cells rapidly produce IL-10, which promotes antigen presenting cell 
(APC)-dependent  TH2  cell  differentiation,  whereas  apoptotic  IL-10-deficient 
cells, as well as living cells, favor TH1 induction (Gao et al., 1998). Furthermore, 
among other stimuli (e.g. PGE2) (Strassmann et al., 1994), IL-10 was reported 
to induce a population of MΦs that produced high levels of IL-10 (Martinez et 
al.,  2008).  Paracrine  and/or  autocrine  IL-10  signaling  then  suppresses 
transcription  of  pro-inflammatory  mediators  in  a  STAT3-dependent  manner 
(O'Shea and Murray, 2008). 
A  further  anti-inflammatory  feature  of  ACs  consists  in  their  ability  to  secrete 
TGF-β. After disruption of the mitochondrial membrane potential in ACs, the 
TGF-β stock is redistributed into the cytosol and subsequently secreted in the 
surrounding tissue (Chen et al., 2001). The immunosuppressive properties of Introduction    26 
TGF-β  consist  in  attenuated  pro-inflammatory  cytokine,  ROS  and  NO 
production, and have been discussed extensively in 3.4.1 and 3.4.2. 
 
FIGURE 3.6: Apoptotic cell-mediated polarization of macrophages. 
Apoptotic cells (ACs) secrete interleukin 4 (IL-4), IL-10, transforming growth factor β 
(TGF-β) and lipid factors, like e.g. lysophosphatidylcholine (LPC) and sphingosine-1-
phosphate  (S1P)  and  expose  oxidized  phosphatidylserine  (PtdSerox)  on  the  outer 
leaflet  of  the  plasma  membrane,  which  induce  polarization  of  macrophages  (MΦs). 
Some unidentified lipid factor and PtdSer induce up-regulation of arginase II (ARG II) 
and  ARG I  respectively  in  MΦs,  thereby  impairing  cytotoxic  nitric  oxide  (NO) 
production. Anti-inflammatory S1P mediates its actions by binding to S1P receptors 
(S1P R)  and  subsequently  provoking  vascular  endothelial  growth factor A  (VEGF A) 
and IL-10 release as well as p38 activation, which induces heme oxygenase 1 (HO-1) 
expression. Then, VEGF A autocrinely binds to the VEGF A receptor (VEGF A R) and 
also contributes to up-regulation of HO-1 in a STAT1/3-dependent way. Furthermore, 
S1P-mediated  activation  of  p38  provokes  HuR-dependent  stabilization  of 
cyclooxygenase 2 (COX 2) mRNA leading to production/secretion of prostaglandin E2 Introduction    27 
(PGE2).  PtdSer  activates  Stabilin-2  on  MΦs,  which  induces  production/secretion  of 
TGF-β,  as  well  as  another,  yet  unidentified,  receptor  provoking  release  of  platelet 
activating factor (PAF). TGF-β, PAF and IL-10 bind to their respective receptors on 
MΦs,  thereby  inhibiting  the  production  of  pro-inflammatory  mediators,  like  tumor 
necrosis factor α (TNF-α), IL-1, IL-6 and IL-12. In addition, PtdSer also activates Mer 
via the bridge molecule Gas6, thereby inhibiting nuclear factor κB (NF-κB)-mediated 
induction of pro-inflammatory cytokines. Activation of PIAS1/sumoylated peroxisome 
proliferator-activated  receptor γ  (PPARγ)/nuclear  receptor  co-repressor  (NCoR)  is  a 
further  mechanism  by  which  PtdSer  inhibits  NF-κB.  Activated  PPARγ  also  impairs 
reactive oxygen species (ROS) production by preventing PKCα-dependent activation of 
NADPH-oxidase. Finally, IL-10 as well as lipid factors secreted by ACs might inhibit the 
expression  of  major  histocompatibility  complex II  (MHC II)  in  MΦs.  ‘?’  designates 
putative/uncharacterized pathways. 
3.4.3.2  Effect of S1P on macrophages 
Besides  the  anti-inflammatory  cytokines  IL-4,  IL-10  and  TGF-β,  ACs  also 
secrete the bioactive lipid mediator S1P (Weigert et al., 2006). S1P emanates 
from the sphingolipid metabolic cascade (see FIGURE 3.7), starting with the 
hydrolysis  of  sphingomyelin  by  sphingomyelinase  (SMase),  which  produces 
ceramide. Thereupon, ceramide can be deacylated by ceramidase (CDase) to 
sphingosine, and sphingosine is phosphorylated by sphingosine kinase (SK) to 
S1P.  Furthermore,  S1P  may  also  be  synthesized  de  novo,  starting  with  the 
condensation of palmitoyl-CoA and serine to 3-ketosphinganine, which is then 
converted  into  ceramide  by  several  reactions.  S1P  turnover  is  mediated  by 
reversible dephosphorylation to sphingosine by S1P phosphatase (SPP) or by 
irrevocable degradation through S1P lyase (SPL) (Le Stunff et al., 2004). Introduction    28 
 
FIGURE 3.7: Sphingolipid metabolism. 
Sphingomyelin is hydrolized by sphingomyelinase (SMase) to ceramide. Ceramide can 
be  transformed  to  sphingosine  by  ceramidase  (CDase)  or  re-converted  to 
sphingomyelin by spingomyelin synthase (SMSyn). Sphingosine is phosphorylated by 
sphingosine  kinase  (SK)  to  sphingosine-1-phosphate  (S1P)  or  re-transformed  to 
ceramide by ceramide synthase (CDSyn). S1P can be hydrolized to sphingosine by 
S1P phosphohydrolase (SPP) or irreversibly degraded by S1P lyase (SPL). S1P may 
also be synthesized de novo through the condensation of serine with palmitoyl-CoA. 
S1P can be exported from cells via ABC transporters (Mitra et al., 2006), but it 
can also be produced extra-cellularly by secreted SK1 and SK2 (Venkataraman 
et al., 2006)(Weigert et al., unpublished data), where it signals by binding to five 
specific G protein-coupled receptors (GPCRs) (S1P1-5). S1P signaling via S1P1-
5 has been linked to a series of important events, like vascular development and 
maturation, cardiac development, directed cell motility and immunity (Spiegel 
and  Milstien,  2003).  S1P  receptors  and  corresponding  down-stream  effector 
kinases are summarized in FIGURE 3.8. Introduction    29 
 
FIGURE 3.8: Sphingosine-1-phosphate receptors and effectors. 
Exported sphingosine-1-phosphate (S1P) binds to five specific receptors (S1P1-5) and 
triggers many signaling pathways either directly or by activating G proteins, like Gq, Gi 
or  G12/13.  Phospholipase C  (PLC),  Rac,  p38,  extracellular  signal-regulated  kinases 
(ERK),  phosphatidylinositol-3 kinase  (PI3K),  Rho,  jun  N-terminal  kinase  (JNK)  or 
adenylyl  cyclase  (ADCY)  constitute  some  examples  of  effectors  mediating  these 
signaling pathways. (PM: plasma membrane) 
Several studies documented the anti-inflammatory (Idzko et al., 2002; Xin et al., 
2004) and anti-apoptotic effects of S1P (Gomez-Munoz et al., 2003; Weigert et 
al.,  2007).  Weigert  et  al.  showed  that  AC-derived  S1P  protects  MΦs  from 
apoptosis, enhances IL-10 and IL-8 expression and attenuates TNF-α as well 
as IL-12p70 release. These anti-apoptotic and anti-inflammatory effects of S1P 
might be mediated, at least in part, by up-regulation of heme oxygenase 1 (HO-
1) (Weis et al., 2009). The authors described a biphasic induction of HO-1, the 
early one (6 hours) being S1P receptor 1/p38-dependent, whereas the second 
one  (24 hours)  was  attributed  to  autocrine  signaling  of  vascular  endothelial 
growth factor A (VEGF-A). HO-1, which metabolizes heme to biliverdin, ferrous 
iron and carbon monoxide, has been described as anti-inflammatory (Deshane 
et al., 2005; Kim et al., 2006; Otterbein et al., 2000) and anti-apoptotic by up-
regulating Bcl-2 and Bcl-XL (Weis et al., 2009). Furthermore, tumor promoting 
properties  have  recently  been  attributed  to  S1P  and  TGF-β  secreted  by 
apoptotic tumor cells. In combination with other AC-derived factors, S1P and 
TGF-β initiate a HIF-1 response in MΦs under normoxic conditions resulting in Introduction    30 
e.g. VEGF release. Based on experiments with MΦs from conditional HIF-1α 
knockout mice, Herr et al. showed that upon stimulation with supernatants of 
ACs, MΦs HIF-1-dependently produce factors that induce CD31 expression in 
murine embryonic stem cells (Herr et al., 2009). 
3.5  Cyclic adenosine monophosphate signaling pathways 
Upon  stimulation  of  a  G protein-coupled  receptor  (GPCR),  the  associated 
heterotrimeric  G protein  exchanges  guanosine  diphosphate  (GDP)  for 
guanosine triphosphate (GTP) on the α-subunit, which is thereby activated and 
dissociates from the βγ-dimer. Then, both the α- and βγ-subunits can initiate or 
inhibit  distinct  signaling  pathways.  Termination  of  GPCR-mediated  signaling 
cascades is achieved by the intrinsic GTPase activity of the α-subunit, which 
hydrolyzes GTP to GDP and then re-associates with the βγ-dimer (Pierce et al., 
2002). 
The  activated  α-subunit  of  the  Gs  subtype  induces  e.g.  the  conversion  of 
adenosine triphosphate (ATP) into cAMP and pyrophosphate (PPi) by activating 
the lyase adenylyl cyclase (Levitzki, 1988). The intracellular second messenger 
cAMP then binds and activates effector or regulator molecules (see FIGURE 
3.9)  such  as  cAMP-gated  ion  channels  (Kaupp  and  Seifert,  2002),  guanine 
nucleotide-exchange proteins directly activated by cAMP (EPACs) (Bos, 2003), 
phosphodiesterases (PDEs) (Houslay and Adams, 2003) and protein kinase A 
(PKA) (Walsh et al., 1968). Termination of cAMP signaling is ensured by PDE 
activity, which hydrolyzes cAMP to AMP (Houslay and Adams, 2003). The main 
intracellular target of cAMP is PKA, a tetrameric holoenzyme consisting of two 
catalytic (C) subunits and a regulatory (R) subunit dimer. Upon cAMP binding to 
the  R-subunits,  the  active  C-subunits  dissociate  and  target  down-stream 
effectors  (Corbin  et  al.,  1973;  Potter  and  Taylor,  1979).  As  broad-spectrum 
serine/threonine  kinases,  the  C-subunits  potentially  phosphorylate  numerous 
substrates,  among  which  the  transcription  factor  cAMP  responsive  element 
binding protein (CREB) is the most prominent (Shaywitz and Greenberg, 1999) 
(see FIGURE 3.9). Introduction    31 
 
FIGURE 3.9: Cyclic adenosine monophosphate signaling pathways. 
Agonist-binding to a G protein-coupled receptor (GPCR) provokes the dissociation of 
the  heterotrimeric  G protein  allowing  the  Gαs-subunit  to  activate  adenylyl  cyclase 
(ADCY),  which  converts  adenosine  triphosphate  (ATP)  to  cyclic  adenosine 
monophosphate  (cAMP)  and  pyrophosphate  (PPi).  The  actions  of  the  second 
messenger cAMP are mediated by targets, like cAMP-gated ion channels, exchange 
proteins directly activated by cAMP (EPAC) and activated catalytic subunits of protein 
kinase A  (PKA).  cAMP  is  eventually  hydrolized  by  phosphodiesterase  (PDE)  to 
adenosine monophosphate (AMP). PKA and PDE are found mostly bound to A kinase-
anchoring proteins (AKAP). 
In  order  to  achieve  specific  signaling,  the  PKA  holoenzyme  has  to  be 
compartmentalized  to  allow  phosphorylation  of  only  a  subset  of  potential 
targets. This confinement is mediated by signal-organizing molecules, so-called 
A kinase-anchoring  proteins  (AKAPs),  which  bind  and  direct  PKA  to  distinct 
subcellular locations (Carnegie and Scott, 2003). Along this line, in opposition to 
the  former  assumption  that  cAMP  diffused  freely  in  the  cytosol  (Kasai  and 
Petersen,  1994),  this  second  messenger  was  suggested  to  accumulate  at 
specific  sites  within  cells.  In  fact,  live-cell  imaging  of  rat  neonatal  cardiac 
myocytes  clearly  visualized  gradients  rather  then  a  uniform  intracellular 
distribution of cAMP (Zaccolo and Pozzan, 2002). 
3.5.1 Properties of A kinase-anchoring proteins 
The  AKAP  family  is  constituted  of  structurally  diverse  members,  although 
sharing  common  motifs.  They  all  contain  a  PKA-anchoring  domain  and  a 
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PKA, they also bind other signaling molecules. The colocalization of PKA with 
other signaling enzymes might be the main feature of AKAPs. These multivalent 
scaffold proteins often unite enzymes for both signal transduction and signal 
termination,  thereby  creating  a  regulatory  site  for  a  determined  signaling 
process (Kapiloff, 2002; Zaccolo et al., 2002). 
The muscle-specific AKAP (mAKAP) is one example of an anchoring protein 
containing  both  regulators  of  cAMP  concentration  and  effectors  of  cAMP 
actions,  which  results  in  a  local  modulation  of  PKA  activation.  The  mAKAP 
complex  consists,  among  others,  of  PKA  and  PDE4D3,  the  latter  being  an 
adaptor protein recruiting ERK5 and EPAC1. 
 
FIGURE 3.10: Constitution of muscle A kinase-anchoring protein. 
Muscle  A kinase-anchoring  protein  (mAKAP)  binds  cyclic  adenosine  monophophate 
(cAMP)-dependent protein kinase A (PKA) and cAMP-hydrolizing phosphodiesterase 
(PDE) and holds them in near proximity. In a feed-back inhibition mechanism, cAMP-
activated  PKA  phosphorylates  PDE4D3  twice,  thereby  enhancing  its  activity  and 
consequently  cAMP  hydrolysis.  However,  PDE4D3  is  also  an  adaptor  protein  for 
extracellular signal-regulated kinase 5 (ERK5) and exchange proteins directly activated 
by cAMP (EPAC). ERK5-dependent phosphorylation inhibits the PDE4D3 activity, while 
high  cAMP  concentrations  activate  EPAC/Rap1,  which  inhibits  mitogen-activated 
protein  kinase  kinase 5  (MEK5),  the  up-stream  kinase  of  ERK5.  Thus,  the  mAKAP 
complex finely tunes cAMP-dependent cellular responses. 
In a feed-back inhibition mechanism, activated PKA phosphorylates PDE4D3 on 
serine 13 and serine 54, thereby increasing the binding affinity for mAKAP as 
well as the catalytic activity of PDE4D3. In addition, ERK5 represents a further 
regulatory  module,  since  this  kinase  phosphorylates  PDE4D3  on  serine 579, 
which decreases phosphodiesterase activity and subsequently increases cAMP 
levels.  However,  sustained  cAMP  concentrations  activate  EPAC1  and 
consequently  Rap1,  resulting  in  the  inhibition  of  ERK5.  Dodge-Kafka  et  al. 
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since the dynamic cAMP signaling depended on the phosphorylation state of 
PDE4D3  (Dodge-Kafka  et  al.,  2005).  Thus,  the  mAKAP  complex  is  an 
integrated and internally regulated network allowing a spatio-temporal control of 
cAMP signaling (see FIGURE 3.10). 
3.6  Regulation of arginase II expression 
There are two ARG isoforms in mammals (Morris, 2004), which catalyze the 
hydrolysis  of  L-arginine  to  L-ornithine  and  urea.  Although  their  amino  acid 
sequences  are  58%  identical  and  their  enzymatic  properties  are  similar, 
transcriptional  regulation  as  well  as  their  tissue,  cellular  and  subcellular 
distributions are different. The hepatic isoform, ARG I is mainly expressed in the 
cytosol of hepatocytes and catalyzes the last step of urea synthesis. In contrast, 
ARG II is located in mitochondria, has wide tissue distribution, with expression 
in kidney, brain, small intestine and in MΦs (Grody et al., 1987; Morris et al., 
1998;  Vockley  et  al.,  1996).  Because  of  its  close  proximity  to  ornithine 
aminotransferase in mitochondria, ARG II is considered to be involved primarily 
in the production of L-ornithine as a precursor of proline (Morris, 2004). Even 
though the two ARG isoforms mostly occur individually, some cell types like 
MΦs express both of them (Barksdale et al., 2004; Morris et al., 1998). Based 
on complex expression patterns, Morris et al. suggested that ARG isoforms may 
play distinct, partially overlapping functional roles in MΦ arginine metabolism. 
Furthermore,  ARG  expression  in  MΦs  modulates  NO  production  through 
competition  with  iNOS  (Freire-de-Lima  et  al.,  2006;  Gotoh  and  Mori,  1999; 
Johann et al., 2007; Morris, 2004; Topal et al., 2006). Despite different opinions 
on  the  mechanism  accounting  for  ARG-dependent  impaired  NO  formation, 
ARG II  seems  to  account  for  an  early  and  ARG I  probably  for  a  late  NO 
modulation  (see  3.4.2).  Another  example  of  differential  ARG I  and  ARG II 
regulation  was  provided  by  Barksdale  et  al.,  who  investigated  the  effect  of 
mediators  released  during  trauma,  such  as  catecholamines,  TGF-β  and  TH2 
cytokines on ARG expression in MΦs. The authors observed that, on the one 
hand isoproterenol synergized with IL-4, IL-13, and TGF-β to increase ARG I 
and  on  the other  with  IL-10  to  up-regulate ARG II  in  RAW264.7 MΦs.  They 
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immunosuppression  observed  after  trauma  by  impairing  NO  production 
(Barksdale et al., 2004). 
Marathe et al. reported that in MΦ cell lines as well as primary MΦs, ARG II is a 
direct  target  of  liver  X  receptor  (LXR),  a  transcription  factor  mediating  anti-
inflammatory  actions  (Marathe  et  al.,  2006).  Along  this  line  ACs,  which  are 
known  to  polarize  MΦs  towards  an  anti-inflammatory  regulatory  phenotype, 
have  also  been  reported  to  secrete  factors  that  up-regulate  ARG II  in  MΦs 
(Johann et al., 2007). 
As  a  critical  enzyme  in  polyamine  biosythesis,  ARG II  has  been  linked  to 
proliferation and/or tissue repair in rheumatoid arthritis, since it was expressed 
in synovial fluid cells from patients with different forms of arthritis. Furthermore, 
stimulation  of  these  cells  with  dibutyryl-cAMP,  PGE2  and  LPS  further  up-
regulated ARG II (Corraliza and Moncada, 2002). ARG II was also shown to 
participate  in  anti-viral  defense  by  providing  the  precursor  for  spermine 
biosynthesis,  which  is  known  to  possess  anti-viral  activity  and  to  mediate 
apoptosis. In fact, ARG II protein and enzymatic activity were induced in Sendai 
virus-infected Jurkat cells in an interferon regulatory factor 3 (IRF-3)-mediated, 
but IFN-independent way (Grandvaux et al., 2005). 
Thus, it is known from literature that ARG II can be induced by several agents, 
like dibutyryl-cAMP, PGE2, LPS, IRF-3, LXR, IL-10/isoproterenol or AC-derived 
mediators,  but  the  underlying  mechanisms  still  have  to  be  identified  and 
characterized. 
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3.7  Aims of the studies 
As professional phagocytes, MΦs engulf ACs to prevent them from undergoing 
secondary  necrosis,  thereby  protecting  the  surrounding  tissue  from  being 
exposed  to  inflammatory  constituents.  Moreover,  as  mentioned  before,  ACs 
polarize  MΦs  towards  a  regulatory  phenotype  (M2c)  (Mosser  and  Edwards, 
2008), characterized by enhanced production of anti-inflammatory IL-10, TGF-
β1 and attenuated pro-inflammatory mediators, like NO. Recently, Johann et al. 
demonstrated  that  ARG II  up-regulation  in  response  to  ACs  or  AC-derived 
mediators attenuated NO production in RAW264.7 MΦs (Johann et al., 2007). 
ARG II  competes  with  iNOS  for  the  common  substrate  L-arginine  thereby 
impairing  NO  formation  (Morris,  2004).  These  findings  corroborated  other 
studies reporting modulation of NO production in MΦs by ARG II (Gotoh and 
Mori, 1999; Topal et al., 2006) (see 3.4.2). Based on these observations, ARG II 
seems  to  be  a  promising  therapeutical  target  in  pathophysiological  settings 
derived  from  detrimental  NO  adjustment  and  thus,  understanding  molecular 
pathways  of  its  regulation  is  necessary.  Surprisingly,  despite  the  important 
contribution  of  ARG II  in  the  regulation  of  NO  production  in  MΦs,  the 
mechanism mediating ARG II up-regulation has not been identified up to date. 
Considering  the  rudimentary  information  on  such  a  pathway,  I  intended  to 
characterize  the  signaling  cascade  used  by  AC-derived  mediators  to  up-
regulate  ARG II  in  MΦs.  Furthermore,  since  the  intracellular  pathways 
responsible  for  the  regulatory  MΦ  phenotype  remain  elusive  and  ARG 
expression is an important hallmark of this type of MΦs, I speculated that the 
elucidation  of  the  ARG II-inducing  mechanism  would  provide  additional 
information on AC-dependent MΦ phenotype switch. 
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4  Materials and Methods 
4.1  Materials 
4.1.1 Cells 
RAW 264.7 cells: 
RAW 264.7 mouse monocytes/macrophages were established from ascites of a 
tumor induced in a male Balb/c mouse by intraperitoneal injection of Abselon 
Leukaemia Virus (A-MuLV) in 1978 (Raschke et al., 1978). 
 
Jurkat T cells: 
Jurkat T cells are derived from a 14 year old boy with acute lymphatic leukemia 
(ALL). This T cell line was established in 1977 (Schneider and Schwenk, 1977). 
 
MCF-7 cells: 
MCF-7  human  breast  adenocarcinoma  cells  were  derived  from  the  pleural 
effusion  of  a  69-year-old  Caucasian  woman  with  metastatic  mammary 
carcinoma in 1970 (Soule et al., 1973). 
 
HEK 293 cells: 
HEK 293 cells were generated by transformation of human embryonic kidney 
cells with sheared adenovirus 5 DNA. This cell line was first described in 1977 
(Graham et al., 1977). 
 
Primary murine macrophages: 
Primary  peritoneal  macrophages  were  isolated  by  peritoneal  lavage  from 
C57BL/6 mice. All procedures performed on these mice followed the guidelines 
of the Hessian animal care and use committee. 
 
4.1.2 Bacteria 
Vectors  were  amplified  in  XL1-Blue
®  supercompetent  bacteria,  except  the 
pcDNA3-FLAG1-MEK5 WT  plasmid  obtained  by  QuikChange
® II XL  site 
directed  mutagenesis,  whose  amplification  occurred  in  XL10-Gold
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ultracompetent cells. Bacteria were provided by Stratagene GmbH (Amsterdam, 
The Netherlands) and are listed in Table 4.1. 
Table 4.1: Bacteria strains 
Bacteria strain  Genotype 
XL1-Blue 
recA1  endA1  gyrA96  thi-1  hsdR17  supE44  relA1  lac  [F´  proAB 
lacIqZ.M15 Tn10(Tetr)]. 
XL10-Gold 
TetrD(mcrA)183  D(mcrCB-hsdSMR-mrr)173  endA1  supE44  thi-1 
recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZDM15 Tn10 (Tetr) Amy 
Camr]. 
 
4.1.3 Chemicals and reagents 
All chemicals were of highest grade of purity and commercially available. Cell 
culture media and supplements came from PAA (Cölbe). Reagents and kits are 
listed in Table 4.2. 
Table 4.2: Reagents and kits 
Chemical/Kit  Provider 
AACOCF3 (phospholipase A2 inhibitor)  Calbiochem (Darmstadt, Germany) 
Allstars negative control siRNA  Qiagen GmbH (Hilden, Germany) 
Amaxa® Nucleofector® Kit V  Lonza Cologne AG (Köln, Germany) 
Direct Cyclic AMP EIA Kit  Assay Designs (Ann Arbor, MI, USA) 
Cellulose syringe filter (0.2-µm)  Roth (Karlsruhe, Germany) 
D-luciferine  AppliChem GmbH (Darmstadt, Germany) 
Forskolin (adenyly cyclase activator)  Alexis Biochemicals (Lörrach, Germany) 
GW4896 (sphingomyelinase inhibitor)  Calbiochem (Darmstadt, Germany) 
HiSpeed Plasmid Maxi Kit  Qiagen GmbH (Hilden, Germany) 
IBMX (nonselective phosphodiesterase 
inhibitor) 
Biomol GmbH (Hamburg, Germany) 
In-Fusion™ Dry-Down PCR Cloning Kit 
Clontech-Takara (Saint-Germain-en-Laye, 
France) 
Janus kinase inhibitor 1  Calbiochem (Darmstadt, Germany) 
JetPEI™ transfection reagent  Polyplus transfection (Illkirch, France) Material and Methods    38 
Chemical/Kit  Provider 
JTE013 (sphingosine-1-phosphate receptor 2 
antagonist) 
Cayman Chemical (Ann Arbor, MI, USA) 
KT5720 (protein kinase A inhibitor)  Biomol GmbH (Hamburg, Germany) 
Luminol (3-Aminophtalhydrazide)  Acros Organics (Geel, Belgium) 
LY294002 (phosphatidylinositol 3-kinase 
inhibitor) 
Alexis Biochemicals (Lörrach, Germany) 
N-oleoyl-ethanolamine (ceramidase inhibitor)  Calbiochem (Darmstadt, Germany) 
ON-TARGETplus SMARTpool siRNA (murine 
extracellular signal-regulated kinase 5 and 
sphingosine-1-phosphate receptor 2) 
Dharmacon RNAi Technologies (Bonn, 
Germany) 
PD98059 (ERK1/2 inhibitor)  Alexis Biochemicals (Lörrach, Germany) 
Proteinase K  New England Biolabs (Frankfurt, Germany) 
QuikChange® XL II site directed 
mutagenesis kit 
Stratagene (Amsterdam, The Netherlands) 
Restriction enzymes (Bgl II, EcoR V, Hind III 
and Sma I) 
New England Biolabs (Frankfurt, Germany) 
Rolipram (phosphodiesterase 4D inhibitor)  Biomol GmbH (Hamburg, Germany) 
SB203580 (p38 inhibitor) 
Sigma-Aldrich GmbH (Deisenhofen, 
Germany) 
siControl nontargeting siRNA 
Dharmacon RNAi Technologies (Bonn, 
Germany) 
Sphingosine-1-phosphate  Avanti (Alabaster, AL, USA) 
SQ22536 (adenyly cyclase inhibitor)  Biomol GmbH (Hamburg, Germany) 
Staurosporine 
Sigma-Aldrich GmbH (Deisenhofen, 
Germany) 
U0126 (MEK1/2/5 inhibitor)  Alexis Biochemicals (Lörrach, Germany) 
U73122 (phospholipase C inhibitor) 
Sigma-Aldrich GmbH (Deisenhofen, 
Germany) 
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4.1.4 Antibodies 
IRDye680 or 800-labelled secondary antibodies from mouse and rabbit were 
obtained from Li-COR Biosciences GmbH (Bad Homburg, Germany) (dilution 
for WB analysis 1:6000). Primary antibodies are listed in Table 4.3. 
Table 4.3: Primary antibodies 
Antibody  Provider  Dil. for WB 
Anti-tubulin  Sigma-Aldrich GmbH (Deisenhofen, Germany)  1:2000 
Anti-actin  Sigma-Aldrich GmbH (Deisenhofen, Germany)  1:2000 
Anti-ARG II  Santa Cruz Biotechnology, Inc. (Heidelberg, Germany)  1:1000 
Anti-CREB-1 (100x)  Santa Cruz Biotechnology, Inc. (Heidelberg, Germany)  1:25 
Anti-S1P2 (EDG-5)  Santa Cruz Biotechnology, Inc. (Heidelberg, Germany)  1:1000 
Anti-ERK1/2  Cell Signaling (Danvers, MA, USA)  1:1000 
Anti-ERK5  Cell Signaling (Danvers, MA, USA)  1:1000 
Anti-HA.11  Covance (Emeryville, CA, USA)  1:1000 
Anti-FLAG  Rockland (Gilbertsville, PA, USA)  1:1000 
 
4.1.5 Plasmids 
Plasmids used in this study are listed in the tables below (Table 4.4 and Table 
4.5). The murine ARG II promoter (mpARG II) was cloned into pGL3-Basic as 
described (Johann et al., 2007) in order to follow mpARG II activity. 
Table 4.4: Reporter plasmids 
Plasmid  Informations on properties  Generation 
pGL3-Basic 
no  promoter  upstream  of  the  luciferase  encoding 
region, ampicillin resistance 
Promega 
(Mannheim, 
Germany) 
pGL3-mpARG II 
mpARG II  (1856 bp),  no  promoter  upstream  of  the 
luciferase encoding region, ampicillin resistance 
(Johann  et  al., 
2007) 
pGL3-mpARG II-
1359 bp 
deletion construct of mpARG II (1359 bp), no promoter 
upstream of the luciferase encoding region, ampicillin 
resistance 
Double  digest  of 
pGL3-mpARG II 
(EcoR V, Bgl II) 
 Material and Methods    40 
Plasmid  Informations on properties  Generation 
pGL3-mpARG II-
442 bp 
deletion construct  of mpARG II (442 bp),  no  promoter 
upstream of the luciferase encoding region, ampicillin 
resistance 
Double  digest  of 
pGL3-mpARG II 
(EcoR V, 
Hind III) 
pGL3-mpARG II-
262 bp 
deletion construct  of mpARG II (262 bp),  no  promoter 
upstream of the luciferase encoding region, ampicillin 
resistance 
Double  digest  of 
pGL3-mpARG II 
(EcoR V, Sma I) 
 
Table 4.5: Over-expression plasmids 
Plasmid  Description of encoded protein  Provider/Production 
pcDNA3-HA1-ERK5N  HA1-tagged truncated form of ERK5 (residues 
1-407) containing the TEY activation motif 
pcDNA3-FLAG1-
MEK5D 
FLAG1-tagged  constitutive  active  form  of 
MEK5,  where  serine 311  and  threonine 315 
were replaced by
 aspartate 
Prof. Eisuke Nishida 
(Kyoto University, 
Japan) 
pcDNA3-FLAG1-
MEK5 WT 
FLAG1-tagged wild type form of MEK5 
QuikChange  point-
mutation of pcDNA3-
FLAG1-MEKD 
 
4.1.6 Oligonucleotides 
Oligonucleotides were bought from Biomers.net GmbH (Ulm, Germany) and are 
listed  in  Table  4.6  in  5’-3’  sence.  Boldface  letters  in  EMSA  and  decoy-
oligonucleotides  indicate  the  consensus  sequence  of  the  CRE-site.  The 
underlined letters represent the mutated bases (AC ￿ TG). Point mutations in 
QuikChange  primers  (boldface  letters)  were  used  to  replace  aspartate  by 
serine 311 and threonine 315 in pcDNA3-FLAG1-MEKD in order to generate an 
over-expression plasmid encoding the FLAG1-tagged wild type form of MEK5. 
Table 4.6: Oligonucleotides 
Primer  5’-forward-3’  5’-reverse-3’ 
mpARG II-CRE 
(EMSA) IRD700-
labeled or unlabeled 
GAG AGA TGC TGA CGT C
AC AGG GCG GTG 
CAC CGC CCT GTG ACG TCA GCA 
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Primer  5’-forward-3’  5’-reverse-3’ 
mpARG II-CRE mut 
(EMSA) unlabeled 
GAG AGA TGC TGT GGT C
AC AGG GCG GTG 
CAC CGC CCT GTG ACC ACA GCA 
TCT CTC 
mpARG II-CRE-decoy 
(decoy approach) 
fluorescein-labeled 
GAG AGA TGC TGA CGT C
AC AGG GCG GTG 
CAC CGC CCT GTG ACG TCA GCA 
TCT CTC 
mpARG II-CRE-decoy 
mut. (decoy approach) 
fluorescein-labeled 
GAG AGA TGC TGT GGT C
AC AGG GCG GTG 
CAC CGC CCT GTG ACC ACA GCA 
TCT CTC 
MEK5 WT 
(QuikChange) 
GGC GTG AGC ACA CAG C
TG GTG AAT TCT ATA GC
C AAG ACG TAT GTT GGA 
AC 
GT TCC AAC ATA CGT CTT GGC TA
T AGA ATT CAC CAG CTG TGT GCT
 CAC GCC 
 
4.1.7 Instruments and Software 
Instruments and software used in this study are listed in Table 4.7 and Table 
4.8. 
Table 4.7: Instruments 
Instruments  Provider 
Autoclave HV 85   BPW GmbH (Süssen, Germany) 
B250 Sonifier   Branson Ultrasonics (Danbury, USA) 
Bacteria clean bench UV/UB 1200  Uniequip GmbH (Martinsried, Germany) 
Bacteria incubator B5042   Heraeus GmbH (Hanau, Germany) 
CASY®   Schärfe System (Reutlingen, Germany) 
Centrifuge 5415 R   Eppendorf GmbH (Hamburg, Germany) 
Centrifuge CR 3.22 and MR23i  Jouan GmbH (Unterhaching, Germany) 
FACSCanto flow cytometer  BD Biosciences GmbH (Heidelberg, Germany) 
Fluorescence  microscope  Axiovert 
200M  
Carl Zeiss MicroImaging Inc (Göttingen, Germany) 
Holten Lamin Air clean bench   Jouan GmbH (Unterhaching, Germany) Material and Methods    42 
Instruments  Provider 
IG 150 (cell culture incubator)   Jouan GmbH (Unterhaching, Germany) 
LabLine Orbit Shaker   Uniequip GmbH (Martinsried, Germany) 
Magnetic stirrer Combimag RCH  IKA  Labortechnik  GmbH  &  Co.  KG  (Staufen, 
Germany) 
Mastercycler®   Eppendorf GmbH (Hamburg, Germany) 
Mini-PROTEAN 3 System   Bio-Rad Laboratories GmbH (Munich, Germany) 
Mithras LB940 multimode reader  Berthold Technologies (Bad Wildbad, Germany) 
NanoDrop ND-1000   Peqlab Biotechnologie GmbH (Erlangen, Germany) 
Nucleofector  Amaxa AG (Cologne, Germany) 
Odyssey infrared imaging system  Li-COR  Biosciences  GmbH  (Bad  Homburg, 
Germany) 
Pure water system Purelab Plus   ELGA LabWater GmbH (Siershahn, Germany) 
Sub-Cell® GT electrophoresis system   Bio-Rad Laboratories GmbH (Munich, Germany) 
Thermomixer 5436   Eppendorf GmbH (Hamburg, Germany) 
Trans-Blot SD blotting machine   Bio-Rad Laboratories GmbH (Munich, Germany) 
Ultrasonic bath Sonorex  Bandelin electronic GmbH (Berlin, Germany) 
UV-Transilluminator gel 
documentation system  
Raytest GmbH (Straubenhardt, Germany) 
 
Table 4.8: Software 
Software  Provider 
AxioVision Software  Carl Zeiss MicroImaging Inc (Göttingen, Germany) 
BD FACSDivaTM Software  BD Biosciences GmbH (Heidelberg, Germany) 
MikroWin 2000 Software  Berthold Technologies (Bad Wildbad, Germany) 
Odyssey 2.1 Software 
Li-COR  Biosciences  GmbH  (Bad  Homburg, 
Germany) 
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4.2  Methods 
4.2.1 Cell biology 
4.2.1.1  Cell culture 
Human Jurkat T cells, RAW264.7 mouse MΦs, human MCF-7 breast carcinoma 
cells  and  primary  murine  peritoneal  MΦs  were  maintained  in  Roswell  Park 
Memorial Institute (RPMI) 1640 medium. Human embryonic kidney (HEK 293) 
cells  were  cultured  in  Dulbecco’s  modified  Eagle’s  medium  (DMEM)  high 
glucose.  Media  were  supplemented  with  10%  heat-inactivated  FCS,  5 mM 
glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were kept in a 
humidified atmosphere of 5% CO2 at 37° C and transferred twice a week. Cells 
were regularly tested to be free of mycoplasma. Cell numbers were determined 
using the cell counter system Casy
®. 
4.2.1.2  Isolation and culture of murine peritoneal macrophages 
Murine  peritoneal  MΦs  were  harvested  by  rinsing  the  peritoneal  cavity  with 
icecold PBS. MΦs were purified by adherence to tissue culture plastic and three 
subsequent  washing  steps,  followed  by  resting  for  3 days  in  RPMI  1640 
supplemented  with  10%  heat-inactivated  FCS,  non-essential  amino  acids, 
pyruvate,  5 mM  glutamine,  100 U/ml  penicillin  and  100  µg/ml  streptomycin 
before individual stimulation. 
4.2.1.3  Generation of apoptotic Jurkat and MCF-7 cells 
MCF-7 or Jurkat cells were treated for 2.5 hours with 0.5  g/ml staurosporine in 
FCS  free  RPMI  1640  supplemented  with  100 U/ml  penicillin,  100 µg/ml
 
streptomycin, washed three times with medium to remove staurosporine and 
incubated for another 5 hours in full medium to generate apoptotic cell (AC)-
conditioned medium (CM) (2.5 * 10
6 ACs/ml medium). Cell death (~80%) was 
confirmed  by  flow  cytometry,  using  annexin V  and  propidium  iodide  staining 
(Immunotech,  Marseille,  France).  ACs  were  centrifuged  for  10 minutes  at 
1000 x g to collect the medium. The
 supernatant of ACs was passed through a 
0.2-µm cellulose
 syringe filter (Roth, Karlsruhe, Germany) to remove remaining 
cells and debris. The filtrated supernatant was taken as CM. I used both CM 
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ACs show similar effects on MΦs (Weigert et al., 2006; Weigert et al., 2007). In 
all experiments, the concentration of CM-M corresponded to the ratio of 1 MΦ to 
2 ACs (ratio 1MΦ:2ACs), while CM-J was used in a ratio of 1 MΦ to 5 ACs 
(ratio 1MΦ:5ACs). 
4.2.1.4  Generation of modified conditioned media 
Jurkat cells were pre-incubated with the sphingomyelinase inhibitor GW4896, 
the  ceramidase  inhibitor  n-oleoyl-ethanolamine  (NOE),  the  phospholipase A2 
(PLA2) inhibitor AACOCF3 or the phospholipase C (PLC) inhibitor U73122 for 
30 minutes, followed by induction of apoptosis as described. In order to digest 
and denaturate proteins, CM was incubated with 50 µg/ml proteinase K at 37° C 
for 1 hour, followed by incubation at 100° C for 1 h our. 
4.2.1.5  Generation  of  a  stable  sphingosine  kinase 2  knock-down  in  MCF-7 
cells 
For  sphingosine  kinase 2  (SK2)  knock-down,  pSilencer-siSK2  was  stably 
transfected  into  MCF-7  cells  (MCF-7-siSK2)  using  Nucleofector  technology 
(Amaxa, Köln, Germany) as described (Weigert et al., 2007). MCF-7-Neo cells 
were generated by nucleofection of MCF-7 cells with the pSilencer 4.1-CMV 
neo control vector (Ambion, Darmstadt, Germany). 
4.2.1.6  Transient transfection 
Transient  transfection  of  different  over-expression  vectors  and  reporter 
plasmids was performed using JetPEI™ cationic polymer transfection reagent 
according to the instructions of the manufacturer. 
For reporter analysis 5 * 10
5 RAW264.7 cells were seeded per well in 24-well 
plates.  Cells  were  allowed  to adhere for  4 hours followed  by  transfection.  In 
brief, 1 µg DNA and 2 µl JetPEI™ transfection reagent were mixed each with 
25 µl 150 mM NaCl per well and vortexed briefly. The JetPEI™ mixture was 
added  to  the  DNA  mixture,  vortexed,  spinned  down  and  incubated  for 
30 minutes at room temperature (RT). Afterwards 50 µl/well of the solution were 
added  to  the  cells,  which  incubated  for  4 hours  before  changing  culture 
medium. Incubations continued for 24 hours, followed by individual stimulation. 
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For over-expression experiments 8 * 10
5 HEK 293 cells were seeded in 10 cm 
dishes.  The  next  day,  cells  were  transfected  with  pcDNA3-HA1-ERK5N  in 
combination  with  pcDNA3-FLAG1-MEK5 WT  or  pcDNA3-FLAG1-MEK5D.  In 
brief, 10 µg DNA (5 µg of each plasmid) and 20 µl JetPEI™ transfection reagent 
were mixed each with 250 µl 150 mM NaCl per dish and vortexed briefly. The 
JetPEI™ mixture was added to the DNA mixture, vortexed, spinned down and 
incubated  for  30 minutes  at  RT.  Afterwards  500 µl/dish  of  the  solution  were 
added  to  the  cells,  which  incubated  for  4 hours  before  starving  overnight, 
followed by individual stimulation. 
Transient  transfection  of  siRNA  was  performed  using  the  Nucleofector
® 
technology from Amaxa biosystems. According to the manufacturer’s protocol, 
2 * 10
6  RAW264.7  MΦs  were  centrifuged  for  10 minutes  at  90 x g  and  re-
suspended in 100 µl Nucleofector
® Solution V. After addition of 3 µg siRNA cells 
were nucleofected using program “D-032”. Transfected cells were immediately 
transferred in 3 ml pre-warmed medium and seeded on 6 cm plates. Culture 
medium  was  changed  after  4 hours.  Experiments  were  done  48 hours  after 
transfection. 
4.2.1.7  CREB decoy experiments 
The decoy approach is based on the ability of living cells to incorporate double-
stranded,  phosphothiorate  stabilized  oligonucleotides,  which  contain  a 
consensus  binding  sequence  for  the  transcription  factor  of  interest.  These 
decoy-oligonucleotides scavenge the transcription factor by occupying the DNA-
binding site, thereby preventing it from binding to promoter regions of target 
genes (von Knethen et al., 1998). RAW264.7 cells were transiently transfected 
with  CRE-oligonucleotides  containing  the  CRE-consensus  site  derived  from 
mpARG II and oligonucleotides with a mutated site as a control (see Table 4.6). 
In  addition,  CREB  decoy-oligonucleotides  contained  a  5'-terminal  fluorescein 
label. One day before transfection cells were seeded at a density of 1 * 10
6 cells 
in  6 cm  dishes.  Oligonucleotides  (3 µM)  were  added  24 hours  prior  to 
experiments.  After  changing  the  medium,  individual  stimulations  were 
performed. Transfection efficiency was determined by counting labeled cells by 
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4.2.2 Biochemistry 
4.2.2.1  Protein determination (Lowry) 
The protein content of cell lysates  was determined by using the DC Protein 
Assay Kit, based on the Lowry method (Lowry et al., 1951). Briefly, a standard 
dilution  series  of  BSA  in  protein  lysis  buffer  (see  Appendix I)  was  prepared 
(0.625  to  10 mg/ml).  2 µl  of  the  the  standard  dilution  series  as  well  as  of 
samples were pipetted in duplicates into a 96-well plate, 20 µl solution A were 
added,  and  then  the  colorimetric  reaction  was  started  by  addition  of  160  l 
solution B.  After  incubation  for  15 minutes  (RT,  shaking),  extinction  was 
measured at 750 nm using the Mithras LB 940 multimode reader. 
4.2.2.2  Nuclear protein extraction 
3 * 10
6 RAW264.7 MΦs were seeded in 10 cm dishes and stimulated with CM 
for  6  respectively  16 hours  with  or  without  pharmacological  inhibitors.  Cells 
were washed with ice-cold PBS and lysed with 200 µl ice cold hypotonic cell 
lysis buffer (see Appendices) for 15 minutes on ice. Nuclei were sedimented by 
centrifugation at 12000 x g for 1 minute and cytosolic fraction was transferred in 
a  new  tube.  Subsequently,  sedimented  nuclei  were  lysed  with  50 µl  nuclear 
lysis buffer (see Appendix I), incubated for 30 minutes on ice and centrifuged at 
12000 x g  for  10 minutes.  Supernatant  was  transferred  in  a  new  tube  and 
protein content was determined using the Lowry method (see 4.2.2.1) 
4.2.2.3  SDS-PAGE/Western analysis 
For Western analysis, 1-3 * 10
6 HEK 293 cells, RAW264.7 or primary peritoneal 
MΦs were stimulated as indicated, scraped off, lysed with 200 µl protein lysis 
buffer  (see  Appendix I)  and  sonicated  for  10  impulses.  Then,  lysates  were 
incubated  on  ice  for  30 minutes  and  vortexed  every  5 minutes.  After 
centrifugation (4° C, 16000 x g, 30 minutes) superna tants were transferred into a 
new  tube.  Protein  concentrations  were  determined  as  described  above  (see 
4.2.2.1). 60-100 µg from RAW264.7 or HEK 293 cells, or 30 µg of protein from 
primary  peritoneal  MΦs  were  mixed  with  4 x SDS  sample  buffer  and 
denaturated  for  10 minutes  at  95° C.  Proteins  were  s eparated  on  10%  SDS-
polyacrylamide geles using 1 x SDS-running buffer and the Mini-PROTEAN 3 
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membrane  by  semi-dry  blotting.  To  prevent  unspecific  binding,  membranes 
were  blocked  with  5%  BSA/TTBS  (see  Appendix I)  for  2 hours  at  RT. 
Afterwards membranes were incubated with antibodies in 5% BSA/TPBS at 4° C 
over night at indicated concentrations (see Table 4.3). For protein detection, 
membrane was washed 3 times with TTBS for 7 minutes and incubated with 
IRDye  secondary  antibodies  (anti-rabbit  or  anti-mouse;  1:6000)  in  5% 
BSA/TTBS for 1 hour at RT. After washing the membrane 3 times for 7 minutes 
proteins  were  visualized  and  densitometrically  analyzed  with  the  Odyssey 
infrared imaging system. 
4.2.3 Molecular biology 
4.2.3.1  Reporter assay 
All reporter assays were performed in duplicate. For reporter analysis cells were 
re-suspended in 100 µl reporter lysis buffer (see Appendix I) and incubated for 
15 minutes  under  shaking  at  RT.  Lysates  were  cleared  by  4000 x g 
centrifugation for 5 minutes. Luciferase activity was measured using a Mithras 
LB 940  multimode  reader.  For  this  purpose,  20 µl  of  the  lysates  were 
transferred  into  a  96-well  plate.  50 µl  reporter  assay  reagent  were  added 
automatically, the plate shaked for 2 seconds and each well was measured for 
10 seconds. Luciferase activity was normalized to protein concentration of each 
sample. 
4.2.3.2  Electrophoretic mobility shift assay (EMSA) 
Except some modifications, EMSA was performed as previously described (Von 
Knethen  and  Brune,  2001; Weigert  et  al.,  2007).  10 µg  nuclear  protein  (see 
4.2.2.2) were incubated with 2 µg poly(dIdC), 2 µl buffer D, 4 µl buffer F (see 
Appendix I), and 250 fmol 5’-IRDye700-labeled mpARG II-CRE oligonucleotides 
(see Table 4.6) in a final volume of 20 µl and incubated for 20 minutes at RT. 
Supershift  analysis  was  performed  by  adding
  4 µg  of  anti-CREB-1  for 
30 minutes  prior  to  incubation  with  5’-IRDye700-labeled  oligonucleotides  for 
20 minutes. The competition assay was performed by adding 25, 50 or 100 fold 
unlabeled  mpARG II-CRE  or  mpARG II-CRE mut  oligonucleotides  (see  Table 
4.6). DNA-protein complexes were resolved on native 4% polyacrylamide gels 
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to  specific  CREB-DNA  binding,  was  determined  using  the  Odyssey  infrared 
imaging system. 
4.2.3.3  Enzyme immunoassay (EIA) 
Determination of cAMP levels in RAW264.7 MΦs was performed by a Direct 
Cyclic  AMP  Enzyme  Immunoassay  Kit  (Assay  Designs)  according  to  the 
manufacturer’s  instructions.  3 * 10
6  RAW264.7  MΦs  were  seeded  in  10 cm 
dishes and starved over night prior to individual stimulations. Cells were lysed 
with 300 µl 0.1 M HCl. 
4.2.3.4  Construction of the pGL3-mpARG II deletion constructs 
An  ARG II  luciferase
  reporter  plasmid  (pGL3-Basic-mpARG II)  containing 
mpARG II upstream of the luciferase gene was generated as described (Johann 
et al., 2007) to follow ARG II promoter activity. Promoter deletion constructs of 
pGL3-Basic-mpARG II  were  produced  in  order  to  narrow  the  region  of 
mpARG II responsible for CM-mediated ARG II up-regulation down. Therefore 
1 µg  of  pGL3-Basic-mpARG II  plasmid  was  double-digested  with  restriction 
enzymes as listed in Table 4.9. The reaction mixture was filled up to 25 µl with 
double-distilled, steril H2O. 
Table 4.9: Double-digestion of plasmids. 
Enzymes  NEBuffer + 
2.5 µg BSA 
Restriction temperature, 
time 
Klenow 
reaction 
EcoR V (0.5 µl); Bgl II (0,5 µl)  Buffer 3  37° C, 1.5  hours  yes 
EcoR V (0.75 µl); Hind  III (0.5 µl)  Buffer 2  37° C,  1.5 hours  yes 
EcoR V (1 µl); Sma I (0.5 µl)  Buffer 4  25° C, 37° C,  each 1,5 hours  no 
 
After  double-digest,  the  restriction  enzymes  were  inactivated  by  heat  (80° C, 
20 minutes).  Bgl II  and  Hind III  endonucleases  produce  5’-overhanging  ends, 
which have to be filled to blunt ends by Klenow reaction in order to be able to 
re-ligate the linearized vectors. The Klenow reaction is achieved at 30° C for 
15° minutes, followed by inactivation at 70° C for 10  minutes (Table 4.10). 
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Table 4.10: Klenow reaction. 
Double-digest reaction  10 µl 
10 x Klenow reaction buffer  2 µl 
dNTPs  2 µl 
Klenow DNA polymerase (1 U/µl)  1 µl 
ddH2O ad 20 µl  5 µl 
 
The linearized vectors were re-ligated by T4 ligase at 22° C for 1 hour followed 
by inactivation for 20 minutes at 65° C. 
Table 4.11: Ligation of linearized vectors. 
Klenow reaction respectively Double-digest  4 µl respectively 2 µl 
10 x Ligation buffer  2 µl 
dNTPs  2 µl 
T4 ligase  5 µl 
ddH2O ad 20 µl  7 µl respectively 9 µl 
 
Double-digest  with  EcoR V  in  combination  with  Bgl II,  Hind III  or  Sma I 
produced a -1359 bp to -1 bp, a -442 bp to -1 bp or a -262 bp to -1 bp construct 
of mpARG II (FIGURE 4.1). Successful cloning of the deletion constructs was 
verified by sequencing (Agowa GmbH, Berlin, Germany). 
 
FIGURE  4.1:  Restriction  enzymes  used  to  generate  mpARG II  promoter 
constructs. 
 
4.2.3.5  Site directed mutagenesis for generation of point mutations 
In order to obtain an over-expression plasmid encoding for the wild type form of 
MEK5,  site  directed  mutagenesis  of  pcDNA3-FLAG1-MEK5D  was  performed 
using QuikChange
® II XL site directed mutagenesis kit. Primers were designed 
according  to  manufacturer’s  instructions  and  are  listed  in  Table  4.6.  5 µl Material and Methods    50 
10 x reaction  buffer,  10 ng  of  the  double-stranded  DNA  template,  125 ng  of 
each primer, 1 µl dNTP mix, 3 µl QuikSolution were mixed and filled up with 
distilled H2O to a final volume of 50 µl. Then 1 µl PfuUltra HF DNA polymerase 
(2.5 U/µl) were added. The reaction was performed with the cycling parameters 
outlined in Table 4.12. After temperature cycling, the reaction tubes were placed 
on ice for 2 minutes to cool the reactions to ≤ 37° C, followed by the digestion of 
non-mutated  parental  DNA  template  with  10  U  DpnI  for  2 hours  at  37° C. 
Mutated plasmids were transformed into XL10-Gold
® Ultracompetent bacteria 
using  the  heat  shock  method  (see  4.2.4.1).  Plasmids  from  potential  positive 
clones  were  isolated  and  verified  by  sequencing  (Agowa  GmbH,  Berlin, 
Germany). 
Table 4.12: Cycling parameters for QuikChange
® II XL method 
Cycles  Segment  Temperature  Time 
1  initial denaturation  95° C  1 minute 
denaturation  95° C  50 seconds 
anneling  60° C  50 seconds 
18 
extension  68° C  7 minutes 
1  final extension  68° C  10 minutes 
 
4.2.4 Microbiology 
4.2.4.1  Transformation of bacteria by heat-shock 
Bacteria were transformed with plasmid DNA by heat-shock. Therefore, 45 µl of 
bacteria glycerol stocks were thawed on ice and 2 µl of β-mercaptoethanol were 
added in order to increase transformation efficiency. After incubation on ice for 
10 minutes  and  swirling  every  2 minutes,  50 ng  plasmid  DNA  were  added, 
followed by another 30 minutes on ice. After heat-shock (40 seconds, 42° C), 
bacteria were incubated for another 2 minutes on ice. For initial growth, 500 µl 
of  pre-heated  SOC  medium  (see  Appendices)  were  added  followed  by  an 
incubation period of 1 hour at 37° C with shaking at  250 rpm. Then, 200 µl were 
inoculated on a LB agar plate containing 100 µg/ml ampicillin and incubated 
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4.2.4.2  Bacterial culture and plasmid preparation 
For preparation of plasmids a single clone from the LB agar plate was picked, 
transferred into 3 ml LB medium containing 100 µg/ml ampicillin and cultured 
over  night  at  37° C  with  shaking  (250 rpm).  The  next   day,  the  culture  was 
transferred  into  200  ml  LB  medium  containing  the  appropriate  antibiotic  and 
again shaked over night at 37° C. Isolation of plasm ids was performed according 
to the manufacturer’s protocol using the NucleoSpin
® Plasmid Kit. DNA content 
was measured with the Nanodrop ND-1000. 
4.2.5 Statistical analysis 
Data represented in graphs are means ± SEM of at least three independent 
experiments. Statistical analysis was done using the paired Student’s t-test and 
considered significant (*) at p £ 0.05, (**) at p £ 0.005 and (***) at p £ 0.0005. 
Western  blots  displayed  in  this  study  are  representative  of  at  least  three 
independent experiments. 
 Results    52 
5  Results 
Johann et al. demonstrated that apoptotic Jurkat cells induced ARG II protein 
expression in MΦs, thereby modulating NO production. Cell-cell contact was not 
necessary since supernatants of ACs, termed CM, showed the same effect. The 
authors concluded that ACs secrete soluble factors responsible for ARG II up-
regulation  (Johann  et  al.,  2007).  I  noticed  that  supernatants  from  apoptotic 
MCF-7 cells also induced ARG II, implicating that its expression is independent 
of the AC type being used. A detailed signaling pathway mediating ARG II up-
regulation in MΦs was still missing. Since ARG expression is a hallmark of the 
regulatory MΦ phenotype (Mantovani et al., 2004b), I assumed that elucidation 
of the underlying pathway(s) could provide general information on intracellular 
mechanisms  responsible  for  the  development  and  maintenance  of  this 
phenotype. 
5.1  Sphingosine-1-phosphate (S1P) from apoptotic cells (ACs) 
activates  S1P  receptor 2  (S1P2)  to  up-regulate  arginase II 
(ARG II) in macrophages (MΦs) 
5.1.1 ACs  secrete  soluble  lipid  factors  that  up-regulate  ARG II 
expression 
To provide information on principal pathways up-regulating ARG II, I first time-
dependently  determined  ARG II  expression  in  response  to  apoptotic  MCF-7 
cell-conditioned medium (CM-M) in RAW264.7 MΦs. ARG II protein expression 
was already detectable after 4 hours, followed by a steady increase up to 30-
fold induction after 20 hours of incubation (FIGURE 5.1 A). These data correlate 
with observations made by Johann et al., who showed a strong ARG II protein 
expression  in  RAW264.7  MΦs  after  24 hours  following  addition  of  apoptotic 
Jurkat cell CM (CM-J) (Johann et al., 2007). 
Having  established  my  experimental  setup,  I  was  interested  in  the 
characterization of the soluble factor(s) in CM mediating ARG II up-regulation. 
In order to analyze the role of proteins in CM-M, I digested them with 50 µg/ml 
proteinase K (at 37° C for 1 hour) followed by denaturation for 1 hour at 100° C. 
This CM-M, lacking functional proteins, still showed ARG II induction in MΦs Results    53 
(FIGURE 5.1 B), excluding AC-derived proteins such as TGF-β, IL-4 and IL-10, 
as the responsible factors. 
 
FIGURE 5.1: CM-M up-regulates ARG II in MΦs in a protein-independent way. 
(A)  MΦs  were  incubated  for  the  indicated  times  with  CM-M.  The  graph  shows 
quantification  of  CM-M-mediated  ARG II  protein  expression  normalized  to  tubulin. 
ARG II expression in RAW264.7 cells was determined by Western analysis. (B) Cells 
were incubated for 16 hours with CM-M or CM-M treated with 50 µg/ml proteinase K 
(prot.K)  at  37° C  for  1 hour,  followed  by  1 hour  at  100° C  in  order  to  digest  and 
denaturate proteins. ARG II expression in RAW264.7 cells was determined by Western 
analysis. 
5.1.2 Lipid  factors  in  apoptotic  cell-conditioned  medium  (CM)  up-
regulate ARG II 
After excluding AC-derived proteins, I concentrated on the possibility of soluble 
lipid  factors  as  the  responsible  mediators.  Taking  into  account  that 
glycerophospholipid as well as sphingolipid metabolism are active in ACs and 
their metabolites are involved in differentiation, immunity and survival of MΦs 
(Goetzl et al., 2004; Lauber et al., 2003; Weigert et al., 2006), I considered the 
possibility  that  they  might  be  involved  in  ARG II  expression.  Therefore,  I 
inhibited the enzymes of glycerophospholipid metabolism PLA2 using AACOCF3 
and PLC using U73122 (FIGURE 5.2 A,B) before inducing apoptosis in Jurkat 
cells. PLA2 hydrolizes phosphatidylcholine (PtdCh) to LPC and arachidonic acid 
(AA)  subsequently  generating  PGs,  while  PLC  produces  inositol 1,4,5-
trisphophate (IP3), diacylglycerol (DAG) and down-stream lysophosphatidic acid 
(LPA)  through  phosphatidylinositol  (PtdIns)  hydrolysis.  Thus,  these  modified 
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of PLA2 respectively PLC products. I exposed RAW264.7 MΦs to CM-JAACOCF3 
and  CM-JU73122,  determined  ARG II  protein  expression  and  observed  no 
alteration  in  comparison  to  CM-J-mediated  ARG II  up-regulation  (FIGURE 
5.2 C).  These  data  suggest  that  AC-derived  glycerophospholipids  LPC,  LPA 
and the second messenger IP3 as well as PGs do not contribute to ARG II up-
regulation in MΦs. 
 
FIGURE 5.2: Contribution of glycerophospholipids to ARG II induction in MΦs. 
(A,B) Simplified schemes of glycerophospholipid metabolisms: Enzyme inhibitors used 
in this study are indicated. (PtdCh: phosphatidylcholine, PtdIns: phosphatidylinositol, 
AA:  arachidonic  acid,  LPC:  lysophosphatidylcholine,  PG:  prostaglandins,  DAG: 
diacylglycerol, IP3: inositol 1,4,5-trisphosphate, LPA: lysophosphatidic acid). (C) Cells 
were incubated for 16 hours with CM-J or modified conditioned media from Jurkat cells 
where PLA2 or PLC had been inhibited with AACOCF3 or U73122. ARG II expression 
in RAW264.7 cells was determined by Western analysis. 
On  the  contrary,  consecutive  inhibition  of  the  sphingolipid  metabolizing 
enzymes (FIGURE 5.3 A) before inducing apoptosis in Jurkat or MCF-7 cells, 
generated modified conditioned media, which were less active in ARG II up-
regulation  (FIGURE  5.3 B,C).  In  fact,  the  SMase  inhibitor  GW4869  or  the 
CDase inhibitor NOE in apoptotic Jurkat cells reduced the potential of CM-Js to 
up-regulate ARG II (FIGURE 5.3 B). These data pointed to the importance of 
the  sphingolipid  mediator  S1P  for  ARG II  expression,  since  ceramide  and 
sphingosine, produced by SMase and CDase respectively, are its precursors. 
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whose CM (CM-MsiSK2) showed a reduced S1P content compared to CM-MNeo 
(4 ng/ml S1P vs. 0.65 ng/ml S1P in the supernatants of 2 * 10
5 apoptotic MCF-
7-Neo  vs.  MCF-7-siSK2  cells)  (Weigert  et  al.,  2007).  I  used  CM-MsiSK2  to 
demonstrate the requirement of S1P for ARG II induction. As expected, CM-
MsiSK2 induced less ARG II expression compared to CM-MNeo (FIGURE 5.3 C), 
thus corroborating the role of S1P for ARG II up-regulation. 
 
FIGURE 5.3: Contribution of sphingolipids to ARG II induction in MΦs. 
(A) Scheme of the sphingolipid metabolism with inhibitors used in this study. (B) Cells 
were incubated for 16 hours with CM-J or modified conditioned media from Jurkat cells 
with  SMase  being  inhibited  with  GW4869  or  CDase  with  NOE.  (C)  MΦs  were 
stimulated for 16 hours with CM-MNeo from MCF-7 cells with a pSilencer 4.1-CMV neo 
control  vector  or  CM-MsiSK2  from  MCF-7  cells  with  a  knock-down  of  SK2.  ARG II 
expression in RAW264.7 cells was determined by Western analysis. 
Since  the  experimental  data  strongly  suggested  S1P  to  be  involved  in  the 
observed  effect,  I  then  analysed  the  impact  of  authentic  S1P  on  ARG II 
expression in MΦs. 0.5 µM authentic S1P had a significant, yet minor effect on 
ARG II  protein  expression  (FIGURE  5.4 A).  Expression  increased  2.3 fold 
compared to controls, while CM-M provoked a 13 fold up-regulation as seen in 
FIGURE 5.1 A. Furthermore, stimulation of RAW264.7 cells with CM-MsiSK2 only 
induced 50% of ARG II protein compared to CM-MNeo. Application of CM-MsiSK2 
in combination with 150 nM S1P restored ARG II expression to levels similar to 
CM-MNeo (FIGURE 5.4 B). Results    56 
 
FIGURE 5.4: S1P contributes to ARG II up-regulation. 
(A) MΦs were incubated with 0.5 µM authentic S1P. (B) Cells were treated with CM-
MNeo, CM-MsiSK2 with or without 150 nM S1P or with 150 nM authentic S1P alone for 
16 hours. ARG II expression in RAW264.7 cells was determined by Western analysis. 
Graphs  show  quantifications  of  ARG II  expression.  Asterisks  mark  statistically 
significant differences. (*) p £ 0.05, (***) p £ 0.0005. 
Since authentic S1P had a minor effect on ARG II protein expression compared 
to CM, I presumed the requirement of at least another, yet unidentified factor for 
robust expression of ARG II. Furthermore, I either used CM-J at a ratio of 5 ACs 
to  1  MΦ  (5ACs:1MΦ)  or  a  lower  ratio  of  3  ACs  to  1  MΦ,  which  was  less 
effective  at  inducing  ARG II  protein.  Addition  of  different  concentrations  of 
authentic S1P to the weaker CM-J stimulus (3ACs:1MΦ) did not restore ARG II 
expression brought about by the stronger CM-J stimulus (5ACs:1MΦ) (FIGURE 
5.5). Thus, the requirement of the postulated second factor was underscored by 
this observation, since its dilution could not be rescued by S1P. 
I  concluded  that  glycerophospholipids,  such  as  LPC  and  LPA,  were  not 
involved, while the sphingolipid S1P was indispensable for ARG II induction. 
5.1.3 S1P mediates ARG II up-regulation via S1P2 
My data showed that S1P was essential for CM-dependent ARG II induction in 
MΦs.  S1P  is  a  pleiotropic  lipid  factor  with  many  actions  mediated  by  five 
receptors  coupled  to  three  different  types  of  G proteins  with  several  effector 
proteins  (see  3.4.3.2).  Considering  the  numerous  potential  mechanisms,  the 
next  step  consisted  in  the  identification  of  the  receptor  on  MΦs  mediating 
ARG II up-regulation in order to constrict the possibilities. Results    57 
 
 
FIGURE 5.5: Sub-optimal concentrations of CM-J cannot be rescued by S1P to 
restore ARG II up-regulation. 
RAW264.7 cells were incubated for 16 hours with CM-J at a ratio of 5 ACs to 1 MΦ 
(5ACs:1MΦ) or 3 ACs to 1 MΦ (3ACs:1MΦ). CM-J (3ACs:1MΦ) was combined with the 
indicated  concentrations  of  S1P.  ARG II  expression  was  determined  by  Western 
analysis. The graph shows quantification of ARG II expression. 
It  is  well  established that S1P  signals  by  binding  to S1P  receptors  (S1P1-5). 
Since  S1P1  and  S1P2  predominate  in  murine  MΦs  (Hughes  et  al.,  2008),  I 
employed specific inhibitors at effective concentrations to clarify which receptor 
was  involved  in  ARG II  up-regulation  (Balthasar  et  al.,  2008).  VPC23019,  a 
S1P1,3  antagonist,  had  no effect  (FIGURE  5.6 A),  while  the S1P2  antagonist 
JTE013 strongly reduced CM-M-mediated ARG II expression (FIGURE 5.6 B). 
This result was underscored by siRNA knock-down of S1P2 in RAW264.7 cells 
(FIGURE  5.6 C).  A  significant  S1P2  knock-down  to  60%  (black  bars) 
significantly reduced ARG II induction to 70% (white bars) compared to controls. 
Thus, S1P in CM mediates ARG II up-regulation by triggering S1P2 signaling in 
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FIGURE 5.6: S1P mediates ARG II up-regulation via S1P2. 
(A,B) Cells were incubated for 16 hours with CM-M with or without the specific S1P1,3 
antagonist VPC23019 or the S1P2 antagonist JTE013 at the indicated concentration. 
Antagonists were pre-incubated for 45 minutes. (C) MΦs were transfected with siRNA 
against S1P2 3 days prior to stimulation with CM-M for 16 hours. ARG II expression 
and S1P2 knock-down in RAW264.7 cells were determined by Western analysis. The 
graph shows quantification of the S1P2 knock-down and ARG II expression. Asterisks 
mark statistically significant differences (p £ 0.05). 
5.2  Extracellular  signal-regulated  kinase 5  (ERK5)  contributes 
to CM-mediated ARG II up-regulation in MΦs 
My previous experimental data demonstrated the contribution of S1P2 signaling 
to ARG II expression in MΦs, thus directing my interest towards potential target 
effectors. 
5.2.1 ERKs contribute to ARG II up-regulation 
To determine the signaling pathway activated by S1P2 in more detail, I used 
specific  inhibitors  of  protein  kinases  that  are  well-known  as  downstream 
effectors  of  S1P  (FIGURE  5.7)  (Kluk  and  Hla,  2002;  Mathieson  and  Nixon, 
2006; Weis et al., 2009). Inhibition of Jak, p38 and PI3K, by the Jak inhibitor 1, 
SB203580  or  LY294002  respectively,  did  not  alter  ARG II  expression,  while 
U0126, a MEK1/2/5 inhibitor, strongly reduced the CM-J-induced ARG II protein 
(FIGURE 5.7). Results    59 
 
FIGURE 5.7: ERKs contribute to ARG II up-regulation. 
RAW264.7 cells were incubated for 16 hours with CM-J and CM-J in combination with 
the  Jak  inhibitor I,  the  PI3K  inhibitor  LY294002,  the  p38  inhibitor  SB203580  or  the 
MEK1/2/5 inhibitor U0126 at the indicated concentration. Inhibitors were pre-incubated 
for  45 minutes.  ARG II  expression  in  RAW264.7  cells  was  determined  by  Western 
analysis. 
5.2.2 ERK5 signaling induces ARG II expression 
MEK1/2 are ERK1/2 up-stream kinases, while MEK5 directly activates ERK5. 
To discriminate between ERK1/2 and ERK5 signaling involved in ARG II up-
regulation,  I  treated  RAW264.7  cells  with  CM-J  from  apoptotic  Jurkat  cells 
where SMase or CDase were inhibited with GW4869 or NOE. Although these 
modified conditioned media failed to induce ARG II protein, they still induced 
ERK1/2 phosphorylation (FIGURE 5.8 A). Furthermore, high concentrations of 
the ERK1/2 inhibitor PD98059 (50 µM) attenuated CM-M-dependent ARG II up-
regulation, while lower doses (10 µM) had no effect, despite inhibiting ERK1/2 
phosphorylation (FIGURE 5.8 B). These findings ruled out the involvement of 
ERK1/2 and suggested ERK5 to up-regulate ARG II. 
 
FIGURE 5.8: ERK1/2 is not involved in ARG II up-regulation. 
(A) RAW264.7 cells were incubated for 16 hours with CM-J or modified conditioned 
media from Jurkat cells where SMase or CDase were inhibited with GW4869 or NOE. 
(B) Cells were incubated for 16 hours with CM-M with or without the ERK1/2 inhibitor 
PD98059  at  the  indicated  concentrations.  The  inhibitor  was  pre-incubated  for 
45 minutes. ARG II expression and ERK1/2 phosphorylation in RAW264.7 cells were 
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In  order  to  corroborate  the  importance  of  ERK5  in  ARG II  expression,  I 
performed  a  siRNA  knock-down  of  ERK5,  which  was  verified  by  Western 
analysis. As expected, reducing ERK5 by roughly 50% (black bars) significantly 
diminished CM-M-mediated ARG II protein expression likewise to approximately 
50%  (white  bars)  (FIGURE  5.9).  Thus,  siRNA  knock-down  of  ERK5  clearly 
demonstrated the participation of ERK5 signaling in CM-mediated ARG II up-
regulation in MΦs. 
 
FIGURE 5.9: ERK5 signaling induces ARG II. 
Transiently transfected RAW264.7 cells (with siRNA against ERK5) were stimulated 
with CM-M for 16 hours. ARG II expression and ERK5 knock-down in RAW264.7 cells 
were determined by Western analysis. The graph shows quantification of the ERK5 
knock-down and ARG II expression. Asterisks mark statistically significant differences 
(p £ 0.05). 
5.3  Cyclic  adenosine  monophosphate  (cAMP)  responsive 
element binding protein (CREB) contributes to ARG II up-
regulation in MΦs 
Since the induction of ARG II by CM-M was detectable after 4 hours at protein 
level  and  increased  constantly  up  to  20 hours  (FIGURE  5.1),  I  assumed 
transcriptional  regulation  to  be  involved.  To  verify  this  presumption  and  to 
identify a possible transcription factor, I performed an analysis of the murine 
ARG II  promoter  (mpARG II)  based  on  luciferase  reporter  assays,  an  EMSA 
analysis and a decoy-approach. Results    61 
5.3.1 Murine ARG II promoter (mpARG II) analysis 
I generated mpARG II constructs by serial deletion of fragments using different 
restriction enzymes (FIGURE 4.1). RAW264.7 MΦs were transfected with the 
respective  mpARG II  constructs  (mpARG II-1856 bp,  -1359 bp,  -442 bp  or  -
262 bp), further cultured for 24 hours and stimulated with CM-J or 0.5 µM S1P 
for 16 hours prior to reporter analysis. In agreement with my assumption that 
transcriptional  regulation  was  taking  place,  CM-J  induced  mpARG II  activity 
about  8 fold  and  S1P  about  1.5 fold  compared  to  unstimulated  controls. 
Interestingly, all promoter constructs including the smallest one of 262 bp still 
displayed  CM-J-mediated  ARG II  promoter  activity  comparable  to  the  whole 
promoter (FIGURE 5.10), implying that the responsible transcription factor binds 
to the 262 bp fragment of mpARG II and thereby enhances ARG II transcription. 
 
FIGURE 5.10: mpARG II analysis. 
Transfected RAW264.7 cells were stimulated for 16 hours with CM-J or 0.5 µM S1P. 
mpARG II activity was measured by luciferase reporter assay. 
5.3.2 CREB contributes to CM-mediated ARG II up-regulation 
The next step consisted in the identification of the transcription factor mediating 
CM-dependent ARG II transcriptional up-regulation in MΦs. For this purpose, I 
performed  in  silico  analysis  of  the  262 bp  fragment  of  the  mpARG II,  which 
revealed, among others, a CREB binding site (FIGURE 5.11). 
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FIGURE 5.11: 262 bp fragment of mpARG II containing a CREB binding site. 
 
Considering  that  this  transcription  factor  can  in  fact  be  activated  by  ERK5 
(Sharma and Goalstone, 2005; Watson et al., 2001), I decided to analyze the 
effect  of  CM  on  CREB  binding  to  the  sequence  of  mpARG II.  Therefore,  I 
incubated RAW264.7 cells with CM-M for 16 hours, isolated nuclear proteins 
followed  by  EMSA  analysis.  Employing  oligonucleotides  containing  the 
mpARG II  CRE  site  showed  significantly  enhanced  binding  of  CREB  in 
response to CM-M (1.8 fold compared to controls) in EMSA. This result was 
reinforced by supershift analysis using an anti-CREB-1 Ab (FIGURE 5.12 A). In 
accompanying  competition  assays,  an  excess  of  unlabeled  oligonucleotides 
(25, 50 or 100 fold excess of unlabeled vs. labeled oligonucleotides) completely 
abolished  the  binding  signal,  while  unlabeled  oligonucleotides  containing  a 
mutation in the CRE site had no effect (FIGURE 5.12 B). 
In order to definitely demonstrate the involvement of CREB in ARG II induction, 
I used a decoy-approach to scavenge active CREB in RAW264.7 MΦs prior to 
its binding to the promoter of its target genes. I transfected RAW264.7 cells with 
3 µM oligonucleotides with the sequence of mpARG II, containing a mutated vs. 
a  non-mutated  CREB  binding  site.  After  culturing  for  another  48 hours, 
RAW264.7 cells were stimulated with CM-M for 16 hours and ARG II expression 
was  subsequently  analyzed  by  Western  blotting.  In  line  with  my  previous 
observations, decoy-oligonucleotides, which scavenged active CREB, blocked 
CM-M-mediated ARG II protein induction. The mutated decoy-oligonucleotides 
did not alter ARG II expression (FIGURE 5.13). 
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FIGURE 5.12: Enhanced CREB binding to mpARG II oligonucleotides. 
(A,B) RAW264.7 cells were stimulated with CM-M for 16 hours. CM-M-mediated CREB 
binding to mpARG II-oligonucleotides was analysed by EMSA. In (A), a supershift was 
performed with an anti-CREB-1 Ab. The graph shows quantification of CREB binding to 
respective  oligonucleotides.  Asterisks  mark  statistically  significant  differences 
(p £ 0.0005).  In  (B),  competition  assays  were  performed  with  non-mutated  (UO)  or 
mutated unlabeled oligonucleotides (mutUO) in 25, 50 or 100 fold excess over labeled 
ones (xLO). 
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FIGURE 5.13: CREB decoy in RAW264.7 MΦs prevents ARG II induction. 
Cells  were  transiently  transfected  with  mutated  or  non-mutated  CREB  decoy-
oligonucleotides  48 hours  prior  to  stimulation  with  CM-M  for  16 hours.  ARG II 
expression was detected by Western analysis. 
Considering the data obtained by mpARG II and EMSA analysis as well as the 
CREB-decoy approach, I conclude that CM enhances CREB activity in MΦs 
thereby inducing the transcription of ARG II. 
5.4  S1P2  and  ERK5  are  required  for  CREB  activation  and 
subsequent ARG II up-regulation in MΦs 
My  experimental  data  so  far  showed  that  CM-triggered  S1P2  and  ERK5 
signaling  as  well  as  CREB  DNA-binding  and  transactivation  induced  ARG II 
expression, but a connection between these single components of the putative 
signaling cascade was still missing. To investigate a possible link between S1P2 
signaling  and  ERK5  phosphorylation  in  the  cascade  provoking  ARG II  up-
regulation,  I  analyzed  the  effect  of  the  S1P2  antagonist  JTE013  on  CM-
mediated ERK5 activation/phosphorylation. Furthermore, I also investigated the 
effect of the S1P2 antagonist JTE013 and the MEK5 inhibitor U0126 on CM-
induced CREB DNA-binding activity to complete the intermolecular relations. 
5.4.1 S1P2 mediates ERK5 phosphorylation 
First, I intended to investigate a possible connection between S1P2 and ERK5 
by  analyzing  the  impact  of  CM-triggered  S1P2  signaling  on  ERK5 
phosphorylation.  However,  Western  analysis  of  endogenous  ERK5 
phosphorylation is known to be difficult. Indeed, I observed a CM-M-dependent 
induction  of  ERK5  phosphorylation  in  RAW264.7  MΦs  but  detection  signals 
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FIGURE 5.14: CM-M induces ERK5 phosphorylation in RAW264.7 MΦs. 
Cells were incubated with CM-M for indicated time periods. ERK5 phosphorylation in 
RAW264.7 cells was determined by Western analysis. 
In order to bypass this experimental inconvenience, I over-expressed MEK5, 
the up-stream kinase of ERK5 in the wild type or constitutively active form, in 
combination  with  an  ERK5  form  containing  the  activation  motif  targeted  by 
active  MEK5.  I performed  this over-expression  experiment  in  HEK 293  cells, 
whose  transfection  can  be  achieved  with  high  efficiency  compared  to  MΦs. 
Given  that  I  wanted  to  analyze  the  link  between  S1P2  signaling  and  ERK5, 
HEK 293  cells  are  appropriate  for  this  approach  because,  like  MΦs,  they 
express  S1P1-3  (Meyer  zu  Heringdorf  et  al.,  2001).  I  transiently  transfected 
these  cells  with  different  expression  plasmids  encoding  HA-tagged  ERK5N 
(truncated form of ERK5 (residues 1-407) containing the TEY activation motif 
targeted by MEK5), FLAG-tagged MEK5 WT (wild type form of the up-stream 
kinase MEK5) or MEKD (constitutively active form of MEK5). Over-expression 
of HA-ERK5N, FLAG-MEK5 WT and FLAG-MEK5D was confirmed by Western 
analysis.  Co-expression  of  HA-ERK5N  and  constitutive  active  FLAG-MEK5D 
was used as a positive control and resulted in the strongest phosphorylation 
signal  of  ERK5N  (FIGURE  5.15 lane 9).  HEK 293  cells  co-expressing  HA-
ERK5N  and  FLAG-MEK5 WT  were  stimulated  with  CM-M.  CM-M  time-
dependently induced ERK5N phosphorylation, starting at 1 hour and increasing 
up  to  8 hours  (FIGURE  5.15 lanes 3-7).  ERK5N  phosphorylation  was 
normalized  to  the  sum  of  the  expression  of  ERK5N  and  MEK WT 
[pERK5/(MEK5+ERK5)].  Enhanced  ERK5N  phosphorylation  was  initiated  by 
S1P2 since the specific antagonist JTE013 [10 µM] significantly reduced CM-M-
mediated ERK5N phosphorylation (FIGURE 5.15 lane 8). Furthermore, 0.5 µM 
authentic  S1P  also  induced  ERK5N  phosphorylation,  which  peaked  after 
6 hours of stimulation (FIGURE 5.16). 
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FIGURE 5.15: S1P2 mediates ERK5N phosphorylation. 
HEK 293 cells were transiently co-transfected with pcDNA3-HA1-ERK5N and pcDNA3-
FLAG1-MEK5 WT or pcDNA3-FLAG1-MEK5D and kept in FCS-free medium overnight. 
Cells were then incubated with CM-M for the indicated time with or without the S1P2 
antagonist  JTE013.  ERK5N  phosphorylation,  HA-tag  and  FLAG-tag  over-expression 
were analyzed by Western blotting. The graph shows quantification of CM-M-mediated 
ERK5N  phosphorylation  normalized  to  the  sum  of  the  expression  of  ERK5N  and 
MEK WT  [pERK5/(MEK5+ERK5)].  Asterisk  marks  statistically  significant  differences 
(p £ 0.05). 
 
 
FIGURE 5.16: Authentic S1P provokes ERK5N phosphorylation. 
HEK 293 cells were transiently co-transfected with pcDNA3-HA1-ERK5N and pcDNA3-
FLAG1-MEK5 WT and kept in FCS-free medium overnight. Cells were then incubated 
with 0.5 µM S1P for the indicated time. ERK5N phosphorylation, HA-tag and FLAG-tag 
over-expression were analyzed by Western blotting. Results    67 
5.4.2 S1P2 and ERK5 induce CREB binding to the target sequence 
in mpARG II 
The link between S1P2, ERK5 and CREB activation had to be confirmed by 
EMSA analysis. The S1P2 antagonist JTE013 and U0126, the inhibitor of the 
up-stream  kinase  of  ERK5,  reduced  CREB  binding  to  oligonucleotides 
containing  the  mpARG II  CRE  site  after  8  as  well  as  16 hours  (FIGURE 
5.17 A,B) demonstrating the importance of S1P2 and ERK5 signaling for CREB 
activation. 
 
FIGURE 5.17: S1P2 and MEK5 provoke CREB binding to target sequence. 
(A,B) RAW264.7 MΦs were incubated with CM-M with or without the S1P2 antagonist 
JTE013 or the MEK inhibitor U0126 at the indicated concentration for 8 or 16 hours. 
JTE013  and  U0126  were  pre-incubated  for  45 minutes.  CREB  DNA-binding  was 
determined by EMSA. 
Furthermore,  a  physiological  relevance  of  S1P2  and  ERK5  signaling  was 
analyzed by using primary peritoneal MΦs from C57BL/6 mice. Similar to the 
effect in RAW264.7 MΦs, CM-M also up-regulated ARG II protein expression in 
primary  murine  MΦs.  Furthermore,  CM-M-mediated  ARG II  up-regulation  in 
peritoneal murine MΦs was reduced as expected by JTE013 as well as U0126 
(FIGURE 5.18). However, in contrast to RAW264.7 MΦs these primary cells 
already express basal levels of ARG II protein. 
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FIGURE 5.18: Physiological relevance of S1P2 and ERK5 signaling. 
Peritoneal  MΦs  from  C57BL/6  mice  were  incubated  with  CM-M  with  or  without  the 
S1P2 antagonist JTE013 or the MEK inhibitor U0126 at the indicated concentration for 
16 hours. JTE013 and U0126 were pre-incubated for 45 minutes. ARG II expression 
was detected by Western analysis. 
Considering my experimental data, I conclude that S1P in CM contributes to 
ARG II up-regulation in MΦs by binding to S1P2, subsequently inducing ERK5 
signaling and provoking CREB activation. 
5.5  Mechanism of ERK5-dependent CREB activation in MΦs 
Finally, I was interested in the activation mechanism of CREB by ERK5. ERKs 
are  proline-directed  kinases  that  cannot  directly  phosphorylate  CREB  at 
serine 133.  Instead,  they  induce  CREB  phosphorylation  by  activating  an 
intermediate kinase of the ribosomal S6 kinase (RSK) family (Watson et al., 
2001) or by influencing the activation of PKA through the regulation of PDE4D3 
and cAMP hydrolysis (Dodge-Kafka et al., 2005). In order to evaluate these two 
options, I decided first to analyze the importance of cAMP signaling for CM-M-
mediated  ARG II  up-regulation  in  MΦs,  since  recently  alveolar  MΦs  were 
shown to display elevated levels of cAMP in response to ACs (Medeiros et al., 
2009) and cAMP/CREB signaling was reported to account for the alternative 
regulatory phenotype of MΦs (Bystrom et al., 2008; Ruffell et al., 2009). 
5.5.1 cAMP signaling contributes to CM-mediated ARG II induction 
To investigate the role of cAMP in ARG II up-regulation in MΦs, I inhibited the 
cAMP-producing  enzyme  adenylyl  cyclase.  RAW264.7 cells  were  stimulated 
with  CM-M  for  16 hours  and  adenylyl  cyclase  was  inhibited  by  the  specific 
inhibitor SQ22536, which had been pre-incubated for 45 minutes. ARG II was 
then analyzed by Western blot. Inhibition of adenylyl cyclase and subsequent 
cAMP  production  impaired  CM-M-mediated  ARG II  up-regulation  (FIGURE 
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FIGURE 5.19: Adenylyl cyclase contributes to ARG II up-regulation. 
RAW264.7 cells were incubated for 16 hours with CM-M or CM-M in combination with 
the adanylyl cyclase inhibitor SQ22536 at the indicated concentration. SQ22536 was 
pre-incubated for 45 minutes. ARG II expression in RAW264.7 cells was determined by 
Western analysis. 
Thus,  cAMP  production  in  response  to  CM  seems  important  for  ARG II 
induction in MΦs. Taking this into consideration, I went on with the analysis of 
PKA participation since this kinase is the main target of cAMP. In accordance to 
the  previous  results,  inhibition  of  the  cAMP  activated  PKA  by  the  specific 
inhibitor  KT5720  also  prevented  CM-M-mediated  ARG II  up-regulation, 
convincingly pointing to the contribution of cAMP and PKA signaling (FIGURE 
5.20). 
 
FIGURE 5.20: PKA contributes to ARG II up-regulation. 
RAW264.7 cells were incubated for 16 hours with CM-M or CM-M in combination with 
the PKA inhibitor KT5720 at the indicated concentration. KT5720 was pre-incubated for 
45 minutes.  ARG II  expression  in  RAW264.7  cells  was  determined  by  Western 
analysis. 
5.5.2 Combined cAMP elevation and phosphodiesterase 4 (PDE4) 
inhibition mimic the CM effect on ARG II expression 
CM-dependent  ARG II  up-regulation  in  MΦs  requires  cAMP/PKA  as  well  as 
ERK5 signaling, so the next step consisted in elucidating the link between these 
two pathways. Considering that ERK5 has been shown to inhibit the cAMP-
hydrolizing  enzyme  PDE4D3,  and  consequently  to  enhance  PKA  activity  by 
augmenting  cAMP  availability  (Dodge-Kafka  et  al.,  2005),  I  presumed  that 
activation of cAMP production with the adenylyl cyclase activator forskolin and 
at the same time inhibition of PDE4 with rolipram would mimic CM-mediated Results    70 
ARG II  up-regulation.  In  fact,  enhanced  cAMP  production  by  forskolin  in 
RAW264.7  MΦs  was  sufficient  to  induce  ARG II  protein,  while  inhibition  of 
PDE4 with rolipram alone had no effect (FIGURE 5.21). This experiment shows 
that  basal  cAMP  levels  are  not  sufficient  for  ARG II  up-regulation,  since 
inhibition of PDE4 did not induce ARG II, and suggests that a cAMP elevating 
stimulus  is  necessary.  Furthermore,  forskolin-mediated  ARG II  up-regulation 
was strongly enhanced by rolipram, suggesting that cAMP/PKA signaling and 
PDE4 inhibition by ERK5 may mediate ARG II up-regulation in my experimental 
system.  Although  forskolin  and  rolipram  provoke  a  similar  effect,  CM-M  still 
shows a stronger induction of ARG II protein expression. 
 
FIGURE 5.21: Elevation of cAMP combined with PDE4 inhibition mimic the CM-M 
effect on ARG II expression. 
RAW264.7  cells  were  incubated  for  16 hours  with  the  adenylyl  cyclase  activator 
forskolin, the PDE4 inhibitor rolipram or both at the indicated concentration, and with 
CM-M. ARG II expression in RAW264.7 cells was determined by Western analysis. 
Along  this  line,  rolipram  enhanced  CM-M-mediated  ARG II  up-regulation 
(FIGURE 5.22) further indicating that regulation of PDE4 contributes to ARG II 
induction. 
 
FIGURE 5.22: Rolipram enhances CM-mediated ARG II induction. 
RAW264.7 cells were incubated for 16 hours with CM-M or CM-M in combination with 
the PDE4 inhibitor rolipram at the indicated concentration. Rolipram was pre-incubated 
for  45 minutes.  ARG II  expression  in  RAW264.7  cells  was  determined  by  Western 
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5.5.3 CM induces cAMP accumulation in RAW264.7 MΦs 
Finally, since cAMP elevation seemed a prerequisite for ARG II up-regulation I 
investigated  the  impact  of  CM-M  on  cAMP  levels  in  RAW264.7  MΦs.  As 
expected, CM-M provoked cAMP accumulation in these cells (FIGURE 5.23 A). 
The  CM-M-dependent  transient  raises  of  cAMP  levels  in  the  first  2 hours  of 
stimulation clearly match the assumption that elevation of cAMP activates PDE4 
in  a  negative  feedback  loop  leading  to  its  hydrolysis.  At  later  time  points, 
corresponding  to  CM-M-mediated  ERK5  phosphorylation/activation  patterns, 
PDE4 seems to be inhibited thereby allowing a consistent increase in cAMP 
levels.  Furthermore,  maximal  CM-M-dependent  cAMP  accumulation 
(7.4 pmol/ml) lay in the same range as maximal forskolin/IBMX-mediated cAMP 
elevation (7.7 pmol/ml) (FIGURE 5.23 B). 
I  hypothesize  that  a yet  unidentified factor  in  CM  mediates  cAMP  elevation, 
which induces PKA activation and consequently CREB phosphorylation in MΦs. 
At  the  same  time,  S1P-mediated  ERK5  activation  provokes  PDE4  inhibition, 
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FIGURE 5.23: CM-M provokes a consistent increase of cAMP in RAW264.7 cells. 
(A)  MΦs  were  incubated  for  the  indicated  times  with  CM-M  (2 independent 
experiments, in each case duplicates). (B) Cells were incubated for the indicated times 
with the adenylyl cyclase activator forskolin (20 µM) and the nonselective PDE inhibitor 
IBMX  (0.5 mM).  IBMX  was  pre-incubated  for  45 minutes  (1 experiment,  duplicates). 
cAMP levels were determined by EIA. Discussion    73 
6  Discussion 
The  remarkable  plasticity  of  macrophages  (MΦs)  allows  them  to  respond 
adequately to many different environmental stimuli. Accordingly,  MΦs evolve 
into  populations  with  heterogeneous  phenotypes  and  complex  functions  in 
tissue  homeostasis  as  well  as  in  innate and  acquired  immunity.  During  host 
defence, MΦs are classically activated and develop e.g. cytotoxic properties, 
among  which  enhanced  NO  production  is  prominent  (Mosser  and  Edwards, 
2008). However, excessive formation of the cytotoxic NO is detrimental for the 
surrounding tissue. In order to dampen and resolve inflammation, MΦs adopt an 
alternative activated phenotype characterized by impaired NO formation. In this 
context,  arginase  (ARG)  expression  has  been  shown  to  modulate  NO 
production  by  competing  with  iNOS  for  the  common  substrate  L-arginine 
(Freire-de-Lima et al., 2006; Gotoh and Mori, 1999; Johann et al., 2007; Morris, 
2004; Topal et al., 2006). Although, there are different opinions concerning the 
mechanism  mediating  ARG-dependent  impaired  NO  formation  (see  3.4.2), 
ARG II seems to account for an early and ARG I probably for a late modulation 
of NO production and a possible explanation will be discussed later (see 6.1.4). 
Recently, Johann et al. demonstrated that pre-incubation of RAW264.7 MΦs 
with apoptotic cell (AC)-conditioned medium (CM) impaired IFNγ-mediated NO 
generation by up-regulating ARG II (Johann et al., 2007). MΦs incubated with 
ACs have been reported to undergo a regulatory-like activation (Fadok et al., 
1998). More precisely, I assume that ACs activate MΦs alternatively thereby 
engendering a regulatory-like phenotype that shares characteristics with wound-
healing  MΦs.  Indeed,  IL-4  and  IL-13  induce  wound-healing  and  IL-10  the 
development  of  regulatory  MΦs  by  definition  (see  FIGURE  3.3).  Since  ACs 
secrete  IL-10  (Gao  et  al.,  1998)  as  well  as  IL-4  (Hodge  et  al.,  2002),  MΦs 
exposed to them are likely to adopt a phenotype between wound-healing and 
regulatory MΦs (FIGURE 6.1). These regulatory-like MΦs may participate in 
resolution of inflammation as well as in tissue remodeling. 
Since  ARG  expression  is  a  hallmark  of  the  regulatory  MΦ  phenotype 
(Mantovani et al., 2004b), I assumed that elucidation of the signaling pathway(s) 
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intracellular mechanisms responsible for the development and maintenance of 
the regulatory MΦ phenotype. 
 
FIGURE 6.1: Postulated regulatory-like MΦ phenotype induced by ACs. 
Alternative M2 MΦ activation is heterogenous and raises different M2 MΦ phenotypes. 
Interleukin 4 (IL-4) and IL-13 induce wound-healing while IL-10 generates regulatory 
MΦs. Since ACs secrete IL-10 as well as IL-4, MΦs exposed to them are likely to adopt 
a phenotype between wound-healing and regulatory MΦs characterized by exibition of 
scavenger (SR) and mannose receptors (MR), release of immunoregulatory factors, 
like transforming growth factor β (TGF-β) and IL-10, up-regulation of arginase (ARG) 
and consequent production of polyamines and the matrix component collagen. 
Worth mentioning in this context is the fact that TAMs have a phenotype similar 
to  MΦs  treated  with  ACs  (Mantovani  et  al.,  2004a).  Thus,  ARG II  might 
contribute  to  their  pro-tumorigenic  properties  by  impairing  NO  production.  In 
addition,  I  speculate  that  the  ARG II  product  L-ornithine,  as  a  precursor  of 
polyamines which are secreted by TAMs (Mantovani et al., 2004a), could also 
facilitate  tumor  growth.  In  fact,  ARG II  has  also  been  reported  to  be  highly 
expressed  in  some  tumors,  especially  in  kidney,  lung,  breast  and  prostate 
cancer cells (Mumenthaler et al., 2008; Porembska et al., 2003; Rotondo et al., 
2008; Tate et al., 2008) and to metabolize L-arginine thereby supplying tumors 
with L-ornithine needed for their rapid growth and at the same time inducing 
T cell dysfunction (Singh et al., 2000; Tate et al., 2008). This T cell dysfunction 
arises  from  L-arginine  depletion  and  subsequent  impaired  CD3ζ  expression, 
which  is  a  key  element  for  T cell  function.  Thus,  ARG II  might  favor  tumor 
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second by supplying the tumor with polyamines (derived from tumor cells or 
MΦs) and third by promoting immune escape. 
Considering  the  important  contribution  of  ARG II  in  the  regulatory  MΦ 
phenotype and in cancer development, as well as the lack of information on the 
molecular mechanisms of its expression, I aimed at elucidating the signaling 
pathway to understand how CM induces ARG II. 
6.1  Mechanism  mediating  ARG II  up-regulation  in  MΦs  in 
response to CM 
6.1.1 AC-derived S1P contributes to ARG II up-regulation 
Digestion  and  denaturation  of  proteins  in  CM  with  proteinase K  and  heat 
inactivation (100° C) did not impair ARG II protein  expression in MΦs, indicating 
that  a  lipid  rather  than  a  protein  up-regulated  ARG II.  Various  bioactive 
glycerophospholipids  and  sphingolipids,  like  IP3,  LPC,  LPA,  ceramide, 
ceramide 1-phosphate  (C1P),  sphingosine  or  S1P  are  involved  in  cellular 
signaling (Hannun and Obeid, 2008; Xu et al., 2003), some of which have been 
reported to be released from ACs (Lauber et al., 2003; Weigert et al., 2006). To 
characterize the ARG II promoting lipid factor(s) present in CM, I decided to 
sequentially  inhibit  lipid  metabolizing  enzymes  that  generate  bioactive  lipids. 
Glycerophospholipids produced by ACs apparently are not involved because 
blocking PLA2 or PLC left ARG II expression unaltered. In contrast, blocking the 
enzymes  of  the  sphingolipid  metabolism  SMase  and  CDase  in  ACs  showed 
significant  effects.  These  observations  pointed  to  the  importance  of 
sphingolipids  and  in  particular  S1P  in  CM-mediated  ARG II  induction,  since 
ceramide  and  sphingosine  are S1P precursors.  The  importance  of  S1P  was 
underscored by using modified CM from MCF-7 cells with a stable SK2 knock-
down, which contained a reduced S1P amount in comparison to normal CM 
(Weigert et al., 2007). Indeed, induction of ARG II by CMsiSK2 was minor and 
could  be  restored  by  adding  150 nM  S1P.  Moreover,  0.5 µM  authentic  S1P 
induced  ARG II  promoter  activity  and  protein  expression.  As  this  was  weak 
compared to the action of CM, this observation suggested the involvement of at 
least another factor secreted/released from ACs. This unidentified factor either 
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autocrine  signaling  by  MΦs.  Furthermore,  sub-optimal  concentrations  of  CM 
were less effective at inducing ARG II protein and S1P did not restore ARG II 
expression  brought  about  by  optimal  ones.  Thus,  the  requirement  of  the 
postulated second factor was underscored by this observation, since its dilution 
could not be rescued by S1P. I can exclude protein factors since CM lacking 
functional  proteins  still  induced  ARG II,  but  have  to  consider  lipids, 
carbohydrates as well as nucleosides. C1P could be one candidate since it has 
been shown to act synergistically with S1P in human alveolar epithelial cells. 
S1P and C1P, while having minor effects by themselves, potentiated production 
of  PGE2  (Pettus  et al.,  2004). This  would fit  to  the  observation  I  made  with 
CMGW4869, depleted in ceramide (precursor of C1P), whose ability to up-regulate 
ARG II in MΦs was strongly impaired. Based on simple pharmacologic inhibition 
of SK with dimethylsphingosine (DMS), Johann et al. originally excluded S1P as 
a mediator of ARG II expression (Johann et al., 2007). However, DMS is rather 
unspecific  and  e.g.  causes  activation  of  the  epidermal  growth  factor  (EGF) 
receptor  (Igarashi  et  al.,  1990),  which  in  turn  can  activate  ERK5  signaling 
(Scapoli et al., 2004) leading to deceiving assumptions. 
6.1.2 S1P contributes to ARG II expression by activating S1P2 
S1P signaling is mediated by activation of specific G protein-coupled receptors. 
Five  S1P  receptors  (S1P1-5)  are  identified  up  to  date.  MΦs  predominantly 
express S1P1, S1P2, and to a much lesser extent S1P3 (Goetzl et al., 2004). 
Furthermore, only S1P1 and S1P2 have been reported in murine MΦs (Hughes 
et al., 2008). 
Antagonizing S1P1,3 with VPC23019 did not seem to alter ARG II expression, 
while  JTE013-mediated  antagonism  as  well  as  siRNA  knock-down  of  S1P2 
demonstated that this receptor signals towards ARG II induction. Similar to my 
observations, Jiang et al. reported that S1P signals through S1P2 in RAW264.7 
MΦs  thereby  enhancing  cellular  responses  triggered  by  isoproterenol  and 
PGE2, while having a minor effect by itself (Jiang et al., 2007). Thus, synergistic 
signaling  of  S1P  with  other  mediators  does  not  seem  unusual.  Further 
experiments  should  consider  MΦ-derived  PGE2  and  IL-10  as  potential 
unidentified second factors, as these mediators are known to induce ARG II as 
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Corraliza and Moncada, 2002; Jiang et al., 2007). Based on pharmacological 
inhibition of COX-2, which failed to restore NO production in MΦs, Johann et al. 
previously considered MΦ-derived PGE2 unlikely to contribute to CM-mediated 
ARG II up-regulation (Johann et al., 2007). However, low levels of PGE2 derived 
from COX-1 may be sufficient to synergize with S1P. 
6.1.3 ERK5 signaling accounts for CM-mediated ARG II induction 
Pharmacological inhibition of well-known downstream effector kinases of S1P 
revealed  that  inhibition  of  MEK1/2/5,  which  are  direct  up-stream  kinases  of 
ERK1/2/5, prevented CM-mediated ARG II induction. A direct role of ERK1/2 
was ruled out, since modified conditioned media that failed to induce ARG II still 
allowed  phosphorylation  of  ERK1/2.  Furthermore,  low  concentrations  of  the 
ERK1/2 inhibitor PD98059 prevented CM-mediated ERK1/2 phosphorylation but 
did not attenuate ARG II expression. Therefore, I assumed that ERK5 signaling 
was  mandatory  for  CM-mediated  ARG II  up-regulation. This  assumption  was 
corroborated  by  siRNA  knock-down  of  ERK5,  which  significantly  reduced 
ARG II expression. In addition to the similarity of their activation motif (Thr-Glu-
Tyr), ERK5 and ERK1/2 share some actions in the regulation of cell proliferation 
and differentiation. However, unlike other MAP kinases, ERK5 does not only 
transmit signals to downstream molecules by phosphorylation but also contains 
a potent transcriptional activation domain within its C-terminus (Morimoto et al., 
2007). 
Previous  studies  revealed  several  ERK5-mediated  cellular  responses  in  e.g. 
cancer (Esparis-Ogando et al., 2002; McCracken et al., 2008), survival or cell 
proliferation (Scapoli et al., 2004; Watson et al., 2001). However, there is little 
known  about  the  role  of  ERK5  in  MΦs.  One  study  reported  LPS-mediated 
activation  of  ERK1/2,  c-Jun  N-terminal  kinase/stress-activated  protein  kinase 
(JNK), p38 and ERK5, which synergistically induced TNF-α gene expression in 
MΦs (Zhu et al., 2000). Furthermore, ERK5 is indispensable for optimal colony-
stimulating factor 1 (CSF-1)-induced survival and proliferation of monocytes and 
MΦs (Rovida et al., 2008). Thus, my results suggest an interesting novel role of 
ERK5 in regulatory MΦ activation, since ARG expression is a hallmark of the 
regulatory phenotype. A further hint for the importance of ERK5 in alternative 
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induction of PPARδ in MΦs, which functioned as transcriptional sensor of dying 
cells.  The  authors  reported  that  MΦs  from  PPARδ  knock-out  mice  were 
impaired in AC clearance due to lower opsonin production. Furthermore, ACs 
failed to suppress the release of pro-inflammatory and to enhance the secretion 
of  anti-inflammatory  cytokines  in  these  MΦs  (Mukundan  et  al.,  2009).  Since 
ERK5/PPARδ association has been shown to enhance PPARδ transcriptional 
activity  in  a  myoblast  cell  line  (Woo  et  al.,  2006),  one  could  speculate  that 
ERK5-dependent  PPARδ  activation  is  a  further  mechanism  contributing  to 
regulatory MΦ activation. These reports, along with my data, strongly suggest a 
crucial role of ERK5 for the development and maintenance of the regulatory MΦ 
phenotype. 
In addition, the simultaneous up-regulation of ERK5 and ARG II in breast and 
prostate cancer might suggest ERK5-mediated induction of ARG II also in these 
cases (Esparis-Ogando et al., 2002; McCracken et al., 2008; Mumenthaler et 
al., 2008; Porembska et al., 2003). 
6.1.4 CREB DNA-binding and transactivation is necessary for CM-
dependent ARG II up-regulation 
CM-dependent ARG II expression seemed to be dependent on transcriptional 
regulation  since  the  protein  accumulated  from  4 hours  up  to  20 hours.  This 
assumption  was  substantiated  by  luciferase  reporter  analysis  of  the  murine 
ARG II promoter (mpARG II). Furthermore, promoter deletion analysis showed 
a  262 bp fragment up-stream of  the  start  codon  to be needed for  luciferase 
reporter expression. In silico analysis of the 262 bp fragment revealed binding 
sites  for  several  transcription  factors,  including  HIF-1,  GATA-1  and  CREB. 
There  have  been  several  reports  showing  that  CREB  is  activated  by  ERK5 
signaling (Sharma and Goalstone, 2005; Watson et al., 2001). Watson et al. 
reported that the ERK5 pathway, triggered by the neurotrophin receptor, was 
necessary for CREB-mediated survival of neurons. The same authors proved 
that  the  expression  of  a  dominant-negative  MEK5  prevented  neurotrophin-
mediated ERK5 activation as well as CREB phosphorylation. Based on these 
observations, I investigated the impact of CREB in CM-mediated ARG II up-
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scavenging  active  CREB  in  RAW264.7  MΦs  by  decoy-oligonucleotides, 
demonstrated its importance for CM-mediated ARG II induction. 
Furthermore, previous studies reported that ARG II mRNA is up-regulated by 8-
bromo-cAMP or dibutyryl-cAMP, thus pointing to the implication of CREB, even 
though the molecular mechanisms were not elucidated (Corraliza and Moncada, 
2002; Morris et al., 1998). Along this line, activation of adenylyl cyclase with 
100 µM forskolin,  which  is  known  to  raise cAMP  levels,  up-regulated  ARG II 
protein  in  RAW264.7  MΦs  in  my  experiment.  A  recent  study  on  tissue 
regeneration demonstrated the importance of CREB for the anti-inflammatory 
M2  gene  expression  in  MΦs  (Ruffell  et  al.,  2009).  CREB  induced 
CCAAT/enhancer binding protein β (C/EBPβ) expression in these cells, which 
subsequently up-regulated IL-10, IL-13 receptor and ARG I. Thus, this might be 
the explanation for an early ARG II and a late ARG I-dependent NO modulation, 
since my data showed a rapid CREB-mediated ARG II induction, while Ruffell et 
al.  reported  that  ARG I  up-regulation  required  antecedent  CREB-dependent 
enhanced C/EBPβ expression. 
6.1.5 S1P2  triggers  ERK5  signaling  and  subsequent  CREB 
activation resulting in ARG II induction 
In order to link the observed signaling events mediated by S1P2, ERK5 and 
CREB, I first analyzed the effect of S1P2 antagonism on CM-dependent ERK5 
phosphorylation, and then the effect of both S1P2 and ERK5 inhibition on CREB 
binding to mpARG II oligonucleotides. 
Antagonism of S1P2 abolished CM-mediated ERK5 phosphorylation, suggesting 
that  S1P  in  CM  directly  binds  to  S1P2,  provokes  MEK5  activation  and 
subsequent ERK5 phosphorylation. Furthermore, authentic S1P was also able 
to induce ERK5 phosphorylation. In line, S1P2 couples to Gq and G12 proteins 
(Siehler and Manning, 2002), which are known to activate ERK5 (Fukuhara et 
al.,  2000).  Antagonizing  S1P2  or  inhibiting  ERK5  also  reversed  CM-induced 
CREB  binding  to  mpARG II  oligonucledotides,  pointing  to  the  importance  of 
S1P2 and ERK5 for its activation. My findings correlate with previous studies 
showing  that  S1P  induces  CREB  activation  in  e.g.  vascular  smooth  muscle 
(Mathieson and Nixon, 2006) and breast cancer cells (Hadizadeh et al., 2008). 
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mediated because it was prevented by the MEK inhibitors PD98059 and U0126 
(Mathieson  and  Nixon,  2006).  Meanwhile,  it  became  evident  that  these 
inhibitors,  originally  assumed  to  be  specific  for  MEK1/2,  also  inhibit  the 
MEK5/ERK5  pathway.  Thus,  there  is  room  for  speculation  that  in  vascular 
smooth muscle S1P also triggers CREB activation by ERK5. 
The  physiological  relevance  of  S1P2  and  ERK  signaling  was  further 
strengthened  by  pharmacological  inhibition  of  CM-mediated  ARG II  up-
regulation  by  JTE013  as  well  as  U0126  in  primary  peritoneal  MΦs  from 
C57BL/6 mice. Although these primary cells already expressed basal levels of 
ARG II  protein  in  contrast  to  RAW264.7  MΦs,  they  still  showed  a  strong 
increase  in  ARG II  amount  upon  CM  stimulation.  A  similar  observation  was 
made  by  Louis  et  al.,  who  noticed  basal  levels  of  ARG II  mRNA  in  isolated 
murine peritoneal MΦs compared to absent expression in RAW264.7 cells. The 
authors also reported comparable ARG II mRNA induction in both primary and 
RAW264.7  MΦs  in  response  to  LPS  (Louis  et  al.,  1998).  Both  observations 
demonstrate that, despite basal levels of ARG II protein, murine peritoneal MΦs 
can  engage  signaling  pathways  strongly  up-regulating  ARG II  protein 
expression. 
Thus,  my  data  suggest  that  CM  contributes  to  a  MΦ  phenotype  switch  by 
enhancing  S1P2  signaling,  activating  ERK5/CREB  and  subsequently  up-
regulating ARG II, which modulates NO production in these cells (FIGURE 6.2). 
6.1.6 Mechanism of CREB activation by ERK5 
Finally, I investigated ERK5-dependent CREB activation in more detail in order 
to  obtain  further  information  on  the  signaling  mechanisms  activated  in  AC-
polarized MΦs that are possibly responsible for the regulatory MΦ phenotype. 
As  proline-directed  kinases,  ERKs  cannot  directly  phosphorylate  CREB  at 
serine 133,  whose  phosphorylation  is  a  prerequisite  for  CREB-mediated 
transcription (Shaywitz and Greenberg, 1999). Instead, they were reported to 
induce CREB phosphorylation in vitro and in vivo by activating an intermediate 
kinase of the RSK family (Watson et al., 2001; Xing et al., 1996). Furthermore, 
ERK5  can  also  influence  the  activation  of  PKA  und  subsequently  CREB, 
through the regulation of PDE4D3 and cAMP hydrolysis (Dodge-Kafka et al., 
2005). Discussion    81 
 
FIGURE 6.2: CM-mediated activation of S1P2, ERK5 and CREB signaling in MΦs. 
S1P in apoptotic cell (AC)-conditioned medium (CM) contributes to ARG II induction by 
binding to S1P2 to activate ERK5 and subsequently cyclic adenosine monophosphate 
responsive  element-binding  protein  (CREB).  Besides  S1P,  an  unidentified  second 
factor  is  required  for  ARG II  up-regulation.  ARG II  contributes  to  alternative 
macrophage  (MΦ)  activation  by  impairing  nitric  oxide  (NO)  production  and  by 
generating the precursor of polyamines. 
In  my  setting  the  PKA-dependent  CREB  activation  seemed  more  probable, 
since ACs have recently been shown to induce cAMP elevation in alveolar MΦs 
(Medeiros et al., 2009), and cAMP as well as CREB signaling were shown to 
account for the regulatory phenotype of MΦs (Bystrom et al., 2008; Ruffell et al., 
2009). 
cAMP was initially considered to be a second messenger able to diffuse freely 
throughout  the  cell  (Kasai  and  Petersen,  1994).  However,  cAMP  specifically 
transduces  signals  from  various  receptors  and  activates  different  cellular 
functions.  The  pleiotropic  actions  of  cAMP  thus  suggest  a  tightly  regulated 
localization  (Zaccolo  and  Pozzan,  2002).  In  fact,  accumulating  evidence 
demonstrated  gradients  in  the  intracellular  distribution  of  cAMP.  These 
gradients were ensured by compartmentation of cAMP regulators and effectors 
through  the  association  with  scaffold  proteins,  the  AKAPs  (Kapiloff,  2002; Discussion    82 
Zaccolo et al., 2002). Furthermore, in striated myocytes and neurons, muscle 
AKAP (mAKAP) was reported to bind cAMP-dependent PKA as well as cAMP-
hydrolyzing  PDE4D3  in  order  to  spatio-temporally  tune  cAMP  signals.  In 
addition, PDE4D3 served as an adaptor protein for EPAC1 and ERK5. In this 
setting, ERK5 favored sustained PKA activation by phosphorylating PDE4D3 
and thereby decreasing the PDE activity (Dodge-Kafka et al., 2005). 
6.1.6.1  Adenylyl cyclase, PKA and PDE4 regulate ARG II expression 
Consistant with the observations mentioned above, pharmacological inhibition 
of adenyly cyclase as well as PKA impaired CM-mediated ARG II up-regulation. 
The importance of cAMP signaling for ARG II expression was further enforced 
by  forskolin-mediated ARG II  induction.  The  assumption  that  ERK5  indirectly 
mediates CREB activation by inhibiting PDE activity was strengthened by using 
the PDE4 inhibitor rolipram. Indeed, forskolin-dependent activation of adenyly 
cyclase  and  subsequent  enhanced  cAMP  levels,  in  combination  with  PDE4 
inhibition,  up-regulated  ARG II  significantly.  Finally,  CM-mediated  ARG II 
expression  was  even  stronger  when  PDE4  was  inhibited.  Forskolin/rolipram-
dependent  ARG II  induction  was  strong  but  still  lower  compared  to  CM, 
indicating  that  the  responsible  factors  in  CM  either  elevate  cAMP  or  inhibit 
PDE4  (or  both)  more  efficiently  than  forskolin/rolipram.  The  most  probable 
explanation might be the instability of rolipram (Krause et al., 1989), resulting in 
weaker inhibition of PDE4 compared to CM. 
Since I showed that S1P in CM activates S1P2, which has been reported to 
activate  adenylyl  cyclase  and  consequently  cAMP  production  (Spiegel  and 
Milstien,  2003),  one  might  wonder  if  S1P2  signaling  mediates  both  ERK5 
activation and the necessary raise in cAMP levels in my system. However, this 
hypothesis seems improbable because authentic S1P alone had a minor effect 
on ARG II protein up-regulation compared to CM. 
6.1.6.2  Postulation of an AKAP complex involved in ARG II up-regulation 
The implication of PKA, PDE4 and ERK5 in the regulation of ARG II expression 
suggests a close proximity of these kinases and diesterase in MΦs similar to 
other  systems  (see  3.5.1).  This  could  be  achieved  by  an  AKAP  complex 
comprising a scaffold protein, PKA, PDE4 and ERK5 thereby regulating cAMP 
signals in MΦs. A potential candidate might be the scaffold protein AKAP95, Discussion    83 
which has recently been shown to play a specific role in the suppression of 
LPS-dependent TNF-α expression by cAMP. In this context, Wall et al. reported 
that  the  main  anti-inflammatory  effects  of  cAMP  in  MΦs  were  specifically 
mediated by PKA (Wall et al., 2009). Furthermore, the observed CM-dependent 
time  response  of  cAMP  levels  also  supported  the  implication  of  an  AKAP 
complex. The transient raises of cAMP suggested an activation of PDE4 in a 
negative feedback loop at early time points and the consistent increase in cAMP 
levels later on pointed to ERK5-mediated inhibition of PDE4. The 1.8 and 1.5-
fold induction of cAMP after stimulation with CM for 1 and 10 minutes resp. 
correlated with an observation made by Medeiros and collegues. They reported 
a 1.5-fold increase of cAMP in alveolar MΦs incubated with ACs for 30 minutes 
(Medeiros et al., 2009). The discrepancy in time between the effect of CM and 
ACs  might  be  explained  by  the  fact  that  ACs  have  to  secret  factors  to  up-
regulate the cAMP production, while these are already present in CM. 
6.2  Concluding remarks 
In conclusion, my study suggests that a yet unidentified factor in CM provokes 
an increase of cAMP levels in MΦs inducing PKA activation. As it is known from 
literature, PKA activity induces a feedback inhibition by enhancing PDE activity 
resulting in cAMP hydrolysis (Carlisle Michel et al., 2004; Dodge et al., 2001). 
However,  concomitant  CM-mediated  S1P2  signaling  activates  ERK5,  which 
probably  further  enhances  PKA  activity  by  inhibiting  PDE4.  Consequently, 
sustained CREB activation then provokes steady ARG II up-regulation, which 
modulates NO production in these cells thereby accounting for regulatory MΦ 
polarization as well as maintenance (FIGURE 6.3). 
Despite the role in alternative MΦ polarization, ARG II has also been tied to 
tumor  biology,  as  I  mentioned  before,  and  to  a  series  of  vascular  diseases 
including asthma and hypertension (King et al., 2004; Xu et al., 2004), since 
these pathophysiological conditions result from arginase-mediated impaired NO 
production. Although I do not provide any direct evidence, one might wonder if 
the  mechanism  described  in  this  study  (accounting  for  ARG II  up-regulation) 
might apply to other systems, like tumor cells or vascular tissue.  
I  hypothesize  that  the  regulation  of  CM-mediated  cAMP  signaling  in  MΦs  is 
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and regulators together. Additional experiments are necessary in order to show 
an  actual  involvement  of  a  scaffold  protein  and  characterize  it.  Then,  CM-
mediated early PDE4 activation followed by ERK5-dependent inhibition should 
be demonstrated. Finally, co-localization of the single modules of this postulated 
complex should complete the evidence. 
 
FIGURE 6.3: Summary of ARG II up-regulation by CM. 
S1P in apoptotic cell (AC)-conditioned medium (CM) binds to S1P2 to activate ERK5. 
Another  unidentified  factor  probably  binds  to  its  receptor  thereby  raising  cyclic 
adenosine  monophosphate  (cAMP)  levels.  The  second  messenger  cAMP  then 
activates target molecules among which protein kinase A (PKA) is the most prominent. 
The  activated  catalytic  subunits  of  PKA  phosphorylate/activate  cAMP  responsive 
element-binding protein (CREB), which binds to CRE on the promoter region of ARG II 
(mpARG II), thereby enhancing its expression. ARG II facilitates macrophage (MΦ) M2 
polarization by modulating nitric oxide (NO) and polyamine production. PKA is probably 
hold  in  close  proximity  to  cAMP-hydrolizing  phosphodiesterase 4  (PDE4)  by  an 
A kinase-anchoring  protein  (AKAP).  ERK5  might  contribute  to  enhanced  cAMP/PKA 
signaling by inhibiting PDE activity. (PM: plasma membrane, ADCY: adenylyl cyclase, 
ATP: adenosine triphosphate, PPi: pyrophosphate, AMP: adenosine monophosphate) Discussion    85 
Furthermore, it would be interesting to analyze the impact of ERK5 depletion on 
MΦ polarization in detail, since this MAPK seems primordial for a sustained 
cAMP  signal  in  MΦs.  A  conditional  knock-out  approach  in  MΦs  would  be 
sensible, in order to circumvent early embryonic lethalty in conventional ERK5 
knock-out mice (Moodley et al., 2003). A study in a tumor model with ERK5 
conditional knock-out MΦs should provide important insights in the role of the 
ERK5 signaling cascade in TAMs and the subsequent effects on tumor cells. In 
this  context,  the  development  of  a  specific  pharmacological  ERK5  inhibitor 
might be a sensible approach to treat disorders, where alternative regulatory 
MΦ activation is detrimental. 
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8  Appendices 
8.1  Buffers and solutions 
8.1.1 Buffer for cell biology 
Phosphate buffered saline (PBS): 
  NaCl   137 mM 
  KCl   2.7 mM 
  Na2HPO4   8.1 mM 
  KH2PO4   1.5 mM 
  ® Adjust pH to 7.4 
8.1.2 Buffers and solutions for protein analysis 
Hypotonic cell lysis buffer: 
HEPES   10 mM 
MgCl2   2 mM 
EDTA   100  M 
KCl   10 mM 
® Adjust pH to 7.9 
Freshly added prior to use: 
DTT   1 mM 
PMSF   0.5 mM 
Protease inhibitor mix 1 x 
 
Nuclear lysis buffer: 
HEPES  50 mM 
KCl   50 mM 
NaCl   300 mM 
EDTA   100  M 
Glycerol   10% (v/v) 
® Adjust pH to 7.9 
Freshly added prior to use: 
DTT   1 mM 
PMSF   0.5 mM 
Protease inhibitor mix 1 x 
 
Protein lysis buffer 
  Tris/HCl   50 mM 
  EDTA   5 mM 
  NaCl   150 mM 
  Nonidet P-40   0.5% (v/v) 
  ® Adjust pH to 8.0 
  Freshly added prior to use:  
  PMSF   0.5 mM 
  DTT   1 mM 
    Protease inhibitor mix 1 x 
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SDS sample buffer (4 x) 
  Tris/HCl   125 mM 
  SDS     2% (v/v) 
  Glycerol   20% (v/v) 
  Bromophenol blue  0.002% (w/v) 
  DTT   5 mM 
  ® Adjust pH to 6.9 
SDS-running buffer 
  Tris/HCl  25 mM 
  Glycine  192 mM 
  SDS    0.7 mM 
  ® Adjust pH to 8.3 
Upper tris buffer (4 x) 
  Tris/HCl  0.5 M 
  ® Adjust pH to 6.8 
Lower tris buffer (4 x) 
  Tris/HCl  1.5 M 
  ® Adjust pH to 8.8 
Sodium dodecyl sulfate (SDS)-polyacrylamide gels 
  Seperating gels  Stacking gel 
  10%  4% 
40% Acrylamide/Bis-acrylamide 
(37.5% : 1.0% w/v) 
2.5 ml  300 µl 
Lower tris buffer (4 x)  2.5 ml   
Upper tris buffer (4 x)    750 µl 
dH2O   4.9 ml  1.95 ml 
10% SDS  100 µl  30 µl 
TEMED  10 µl  2.5 µl 
10% (w/v) ammonium persulfate  100 µl  25 µl 
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Blotting buffer: 
  Tris-HCl   25 mM 
  Glycine   192 mM 
  Methanol  20% (v/v) 
  ® Check pH to be 8.3 
TBS (tris buffered saline) 
  Tris/HCl   50 mM 
  NaCl   140 mM 
  ® Adjust pH to 7.4 
TTBS 
  Tween-20  0.06% (v/v) 
  ® in TBS 
 
8.1.3 Buffers for molecular biology and microbiology  
SOC medium 
  Tryptone   20 g/l  
  Yeast extract  5 g/l 
  NaCl  0.5 g/l 
  MgCl2  10 mM 
  MgSO4  10 mM 
  Glucose  2 mM 
EMSA running buffer 
Running buffer (glycerol tolerant)  
(Purchased from Amersham Biosciences Europe GmbH, Freiburg, Germany) 
Native acrylamide gels 
  Separating gels 
  4% 
40% Acrylamide/Bis-acrylamide 
(29% : 1.0% w/v) 
1 ml 
1 x glycerol tolerant  0.5 ml 
dH2O   8.5 ml Appendices    104 
TEMED  32 µl 
10% (w/v) ammonium persulfate  100 µl 
 
8.1.4 Buffers for luciferase assay 
Luciferase lysis buffer 
  Tris-H3PO4  125 mM 
  DTT  10 mM 
  Triton X 100  5% 
  Glycerol  50% 
  ® Adjust pH to 7.8 
Luciferase assay reagent 
  Tricine    20 mM 
  (MgCO3)4 x Mg(OH)2  x 5 H2O  1.07 mM 
  MgSO4 x 7 H2O    2.67 mM 
  EDTA-K
+    100 µM 
  DTT    33.3 mM 
  ATP    530 µM 
  Coenzyme A lithium    0.213 mg/ml 
  D-luciferine    470 mM 
  ® Check pH to be 7.8 
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